# EDGAR Filing Document

**Accession Number:** 0001776932
**File Stem:** 0001776932-23-000005
**Filing Date:** 2023-2
**Character Count:** 162056
**Document Hash:** 4ace81ea6c1d410716f4363f019a3c97
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001776932-23-000005.hdr.sgml**: 20230202

**ACCESSION NUMBER**: 0001776932-23-000005

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 107

**CONFORMED PERIOD OF REPORT**: 20221224

**FILED AS OF DATE**: 20230202

**DATE AS OF CHANGE**: 20230202

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MedMen Enterprises, Inc.
- **CENTRAL INDEX KEY:** 0001776932
- **STANDARD INDUSTRIAL CLASSIFICATION:** RETAIL-RETAIL STORES, NEC [5990]
- **IRS NUMBER:** 981431779
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56199
- **FILM NUMBER:** 23580886

**BUSINESS ADDRESS:**
- **STREET 1:** 10115 JEFFERSON BOULEVARD
- **CITY:** CULVER CITY
- **STATE:** CA
- **ZIP:** 90232
- **BUSINESS PHONE:** 4243302082

**MAIL ADDRESS:**
- **STREET 1:** 10115 JEFFERSON BOULEVARD
- **CITY:** CULVER CITY
- **STATE:** CA
- **ZIP:** 90232

?xml version="1.0" ? mmen-20221224

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 10-Q**

⌧ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended December 24, 2022**

**OR**

□ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from ________ to ________**

Commission file number 000-56199

**MEDMEN ENTERPRISES INC.**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **British Columbia** | **98-1431779** |
| **(State or other jurisdiction of<br>incorporation or organization)**<br>**8740 S Sepulveda Blvd, Suite 105,**<br>**Los Angeles, California** | **(I.R.S. employer<br>identification no.)**<br>**90045** |
| **(Address of principal executive offices)** | **(Zip code)** |

---

**(424) 330-2082**

**(Registrant's telephone number, including area code)**

**Securities registered pursuant to Section 12(b) of the Act:**

**None.**

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes □ No ⌧

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large Accelerated Filer | □ | Accelerated Filer | ⌧ |
| Non-Accelerated Filer | □ | Smaller Reporting Company | ⌧ |
| | | Emerging Growth Company | ⌧ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financing accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes □ No ⌧

As of January 30, 2023, the registrant had 1,308,619,247 Class B Subordinate Voting Shares outstanding.

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**MEDMEN ENTERPRISES, INC.**

**QUARTERLY REPORT ON FORM 10-Q**

**FOR THE PERIOD ENDED DECEMBER 24, 2022**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| | | **Page** |
| **<u>[FINANCIAL INFORMATION](#icb45d2f215b8492596aebaa3e07e76d2_16)</u>** | **<u>[FINANCIAL INFORMATION](#icb45d2f215b8492596aebaa3e07e76d2_16)</u>** | |
| **<u>[Part I](#icb45d2f215b8492596aebaa3e07e76d2_16)</u>** | **<u>[Part I](#icb45d2f215b8492596aebaa3e07e76d2_16)</u>** | |
| **<u>[ITEM 1:](#icb45d2f215b8492596aebaa3e07e76d2_19)</u>** | <u>[Condensed Consolidated Balance Sheets (Unaudited)](#icb45d2f215b8492596aebaa3e07e76d2_22)</u> | [1](#icb45d2f215b8492596aebaa3e07e76d2_22) |
| | <u>[Condensed Consolidated Statements of Operations (Unaudited)](#icb45d2f215b8492596aebaa3e07e76d2_25)</u> | [2](#icb45d2f215b8492596aebaa3e07e76d2_25) |
| | <u>[Condensed Consolidated Statements of Shareholders' Equity (Unaudited)](#icb45d2f215b8492596aebaa3e07e76d2_28)</u> | [3](#icb45d2f215b8492596aebaa3e07e76d2_28) |
| | <u>[Condensed Consolidated Statements of Cash Flows (Unaudited)](#icb45d2f215b8492596aebaa3e07e76d2_34)</u> | [5](#icb45d2f215b8492596aebaa3e07e76d2_34) |
| | <u>[Notes to Condensed Consolidated Financial Statements (Unaudited)](#icb45d2f215b8492596aebaa3e07e76d2_37)</u> | [7](#icb45d2f215b8492596aebaa3e07e76d2_37) |
| **<u>[ITEM 2:](#icb45d2f215b8492596aebaa3e07e76d2_109)</u>** | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#icb45d2f215b8492596aebaa3e07e76d2_109)</u> | [28](#icb45d2f215b8492596aebaa3e07e76d2_109) |
| **<u>[ITEM 3:](#icb45d2f215b8492596aebaa3e07e76d2_142)</u>** | <u>[Quantitative and Qualitative Disclosure About Market Risk](#icb45d2f215b8492596aebaa3e07e76d2_142)</u> | [37](#icb45d2f215b8492596aebaa3e07e76d2_142) |
| **<u>[ITEM 4:](#icb45d2f215b8492596aebaa3e07e76d2_145)</u>** | <u>[Controls and Procedures](#icb45d2f215b8492596aebaa3e07e76d2_145)</u> | [37](#icb45d2f215b8492596aebaa3e07e76d2_145) |
| **<u>[OTHER INFORMATION](#icb45d2f215b8492596aebaa3e07e76d2_148)</u>** | **<u>[OTHER INFORMATION](#icb45d2f215b8492596aebaa3e07e76d2_148)</u>** | |
| **<u>[Part II](#icb45d2f215b8492596aebaa3e07e76d2_148)</u>** | **<u>[Part II](#icb45d2f215b8492596aebaa3e07e76d2_148)</u>** | |
| **<u>[ITEM 1:](#icb45d2f215b8492596aebaa3e07e76d2_151)</u>** | <u>[Legal Proceedings](#icb45d2f215b8492596aebaa3e07e76d2_151)</u> | [39](#icb45d2f215b8492596aebaa3e07e76d2_151) |
| **<u>[ITEM 1A:](#icb45d2f215b8492596aebaa3e07e76d2_154)</u>** | <u>[Risk Factors](#icb45d2f215b8492596aebaa3e07e76d2_154)</u> | [39](#icb45d2f215b8492596aebaa3e07e76d2_154) |
| **<u>[ITEM 2:](#icb45d2f215b8492596aebaa3e07e76d2_157)</u>** | <u>[Unregistered Sales of Equity Securities](#icb45d2f215b8492596aebaa3e07e76d2_157)</u> | [39](#icb45d2f215b8492596aebaa3e07e76d2_157) |
| **<u>[ITEM 3:](#icb45d2f215b8492596aebaa3e07e76d2_160)</u>** | <u>[Defaults Upon Senior Securities](#icb45d2f215b8492596aebaa3e07e76d2_160)</u> | [39](#icb45d2f215b8492596aebaa3e07e76d2_160) |
| **<u>[ITEM 4:](#icb45d2f215b8492596aebaa3e07e76d2_163)</u>** | <u>[Mine Safety Disclosure](#icb45d2f215b8492596aebaa3e07e76d2_163)</u> | [39](#icb45d2f215b8492596aebaa3e07e76d2_163) |
| **<u>[ITEM 5:](#icb45d2f215b8492596aebaa3e07e76d2_166)</u>** | <u>[Other Information](#icb45d2f215b8492596aebaa3e07e76d2_166)</u> | [39](#icb45d2f215b8492596aebaa3e07e76d2_166) |
| **<u>[ITEM 6:](#icb45d2f215b8492596aebaa3e07e76d2_169)</u>** | <u>[Exhibits](#icb45d2f215b8492596aebaa3e07e76d2_169)</u> | [40](#icb45d2f215b8492596aebaa3e07e76d2_169) |
| <u>[Signatures](#icb45d2f215b8492596aebaa3e07e76d2_172)</u> | | [41](#icb45d2f215b8492596aebaa3e07e76d2_172) |

---

i

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**Use of Names**

In this Quarterly Report on Form 10-Q, unless the context otherwise requires, the terms "we," "us," "our," "Company," "Corporation" or "MedMen" refer to MedMen Enterprises Inc. together with its wholly-owned subsidiaries.

**Disclosure Statement Regarding Forward-Looking Statements**

*This Quarterly Report on Form 10-Q contains statements that we believe are, or may be considered to be, "forward-looking statements". All statements other than statements of historical fact included in this document regarding the prospects of our industry or our prospects, plans, financial position or business strategy may constitute forward-looking statements. In addition, forward-looking statements generally can be identified by the use of forward-looking words such as "may," "will," "expect," "intend," "estimate," "foresee," "project," "anticipate," "believe," "plan," "forecast," "continue" or "could" or the negative of these terms or variations of them or similar terms. Furthermore, forward-looking statements may be included in various filings that we make with the Securities and Exchange Commission (the "****SEC****"), press releases or oral statements made by or with the approval of one of our authorized executive officers. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot assure you that these expectations will prove to be correct. These forward-looking statements are subject to certain known and unknown risks and uncertainties, as well as assumptions that could cause actual results to differ materially from those reflected in these forward-looking statements. These known and unknown risks include, without limitation: marijuana remains illegal under U.S. federal law, and enforcement of cannabis laws could change; the Company may face limitations on ownership of cannabis licenses; the Company may become subject to U.S. Food and Drug Administration or the U.S. Bureau of Alcohol, Tobacco and Firearms; the Company may face difficulties acquiring additional financing; the Company operates in a highly regulated sector and may not always succeed in complying fully with applicable regulatory requirements in all jurisdictions where we carry on business; the Company is subject to general economic risks; the Company may be negatively impacted by challenging global economic condition; the Company is subject to risks arising from epidemic diseases, such as the recent outbreak of COVID-19; the Company may face difficulties in enforcing its contracts; the Company is subject to taxation in Canada and the United States; cannabis businesses are subject to unfavorable tax treatment; cannabis businesses may be subject to civil asset forfeiture; the Company is subject to proceeds of crime statutes; the Company faces security risks; competition for the acquisition and leasing of properties suitable for the cultivation, production and sale of medical and adult use cannabis may impede our ability to make acquisitions or increase the cost of these acquisitions, which could adversely affect our operating results and financial condition; the Company faces risks related to its products; the Company is dependent on the popularity of consumer acceptance of the Company's brand portfolio; the Company faces risks related to its insurance coverage and uninsurable risks; the Company is dependent on key inputs, suppliers and skilled labor; the Company must attract and maintain key personnel; the Company's business is subject to the risks inherent in agricultural operations; the Company's sales are difficult to forecast; the Company's products may be subject to product recalls; the Company may face unfavorable publicity or consumer perception; the Company faces intense competition; and additional issuances of Subordinate Voting Shares may result in dilution. Further information on these and other potential factors that could affect the Company's business and financial condition and the results of operations are included in the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the SEC on September 9, 2022, and elsewhere in the Company's filings with the SEC, which are available on the SEC's website or on the Company's website at https://investors.medmen.com/. Readers are cautioned not to place undue reliance on any forward-looking statements contained in this document, which reflect management's opinions only as of the date hereof. Except as required by law, we undertake no obligation to revise or publicly release the results of any revision to any forward-looking statements. You are advised, however, to consult any additional disclosures we make in our reports to the SEC. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this document.*

ii

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**PART I — FINANCIAL INFORMATION**

**ITEM 1. CONDENSED CONSOLIDATED FINANCIAL INFORMATION**

**MEDMEN ENTERPRISES INC.**<br>**Condensed Consolidated Balance Sheets (Unaudited)**<br>*(Amounts Expressed in United States Dollars, Except for Share Data)*<br>

---

| | | |
|:---|:---|:---|
| | **December 24,<br>2022** | **June 25,<br>2022** |
|  | *(unaudited)* | *(audited)* |
| **ASSETS** |  |  |
| Current Assets: |  |  |
| &nbsp;&nbsp;Cash and Cash Equivalents | $15605362 | $10795999 |
| &nbsp;&nbsp;Accounts Receivable and Prepaid Expenses | 5415701 | 7539767 |
| &nbsp;&nbsp;Inventory | 13675322 | 10010731 |
| &nbsp;&nbsp;Assets Held for Sale | 43611513 | 123158751 |
| &nbsp;&nbsp;Receivable for Assets Held for Sale | 11500000 |  |
| &nbsp;&nbsp;Other Assets | 10403527 | 9990992 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets | 100211425 | 161496240 |
| Operating Lease Right-of-Use Assets | 34275701 | 47649270 |
| Property and Equipment, Net | 57645329 | 64107792 |
| Intangible Assets, Net | 32653134 | 35746114 |
| Goodwill | 9810049 | 9810049 |
| Other Non-Current Assets | 3879373 | 4414219 |
| **TOTAL ASSETS** | $**238475011** | $**323223684** |
| **LIABILITIES AND SHAREHOLDERS' EQUITY** |  |  |
| **LIABILITIES:** |  |  |
| &nbsp;&nbsp;Current Liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts Payable and Accrued Liabilities | $42926092 | $38905818 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income Taxes Payable | 67472697 | 58646291 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Liabilities | 16591825 | 16704283 |
| &nbsp;&nbsp;&nbsp;&nbsp;Derivative Liabilities | 3642777 | 6749563 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current Portion of Operating Lease Liabilities | 11897467 | 10925128 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current Portion of Finance Lease Liabilities | 4294333 | 4061273 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current Portion of Notes Payable | 66294249 | 97003922 |
| &nbsp;&nbsp;&nbsp;&nbsp;Liabilities Held for Sale | 24524988 | 86595102 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Liabilities | 237644428 | 319591380 |
| &nbsp;&nbsp;Operating Lease Liabilities | 40724983 | 50917244 |
| &nbsp;&nbsp;Finance Lease Liabilities | 27288988 | 26553287 |
| &nbsp;&nbsp;Other Non-Current Liabilities | 2846182 | 3082277 |
| &nbsp;&nbsp;Deferred Tax Liability | 38459344 | 35213671 |
| &nbsp;&nbsp;Senior Secured Convertible Credit Facility | 146193049 | 132005663 |
| &nbsp;&nbsp;Notes Payable | 74110205 | 74372898 |
| &nbsp;&nbsp;**TOTAL LIABILITIES** | **567267179** | **641736420** |
| **SHAREHOLDERS' EQUITY:** |  |  |
| &nbsp;&nbsp;Preferred Shares (no par value, unlimited shares authorized and no shares issued and outstanding) |  |  |
| &nbsp;&nbsp;Subordinate Voting Shares (no par value, unlimited shares authorized, 1,302,129,084 and 1,301,423,950 shares issued and outstanding as of December 24, 2022 and June 25, 2022, respectively) |  |  |
| &nbsp;&nbsp;Additional Paid-In Capital | 1060236631 | 1057228873 |
| &nbsp;&nbsp;Accumulated Deficit | (913798904) | (901758875) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Equity Attributable to Shareholders of MedMen Enterprises Inc. | 146437727 | 155469998 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-Controlling Interest | (475229895) | (473982734) |
| &nbsp;&nbsp;**TOTAL SHAREHOLDERS' EQUITY** | **(328792168)** | **(318512736)** |
| **TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY** | $**238475011** | $**323223684** |

---

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements (Unaudited).

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**MEDMEN ENTERPRISES INC.**<br>**Condensed Consolidated Statements of Operations (Unaudited)**<br>*(Amounts Expressed in United States Dollars, Except for Share Data)*<br>

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 24,<br>2022** | **December 25,<br>2021** | **December 24,<br>2022** | **December 25,<br>2021** |
| Revenue | $29554100 | $35517161 | $59598153 | $72253065 |
| Cost of Goods Sold | 14501052 | 17637003 | 29601351 | 36986993 |
| Gross Profit | 15053048 | 17880158 | 29996802 | 35266072 |
| Operating Expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;General and Administrative | 18341221 | 31292754 | 36452557 | 63941988 |
| &nbsp;&nbsp;&nbsp;Sales and Marketing | 551106 | 1007255 | 994897 | 1600479 |
| &nbsp;&nbsp;&nbsp;Depreciation and Amortization | 3477086 | 6379865 | 7423606 | 12203482 |
| &nbsp;&nbsp;&nbsp;Realized and Unrealized Changes in Fair Value of Contingent Consideration |  | (301459) | (863856) | (301459) |
| &nbsp;&nbsp;&nbsp;Impairment Expense | 5052995 |  | 6716906 | 435241 |
| &nbsp;&nbsp;&nbsp;Other Operating (Income) Expense | (5634350) | 630971 | (7544063) | 2829999 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Operating Expenses | 21788058 | 39009386 | 43180047 | 80709730 |
| Loss from Operations | (6735010) | (21129228) | (13183245) | (45443658) |
| Non-Operating (Income) Expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest Expense | 9686929 | 8077496 | 19739620 | 16249257 |
| &nbsp;&nbsp;&nbsp;Interest Income | (27991) | (22907) | (28024) | (45915) |
| &nbsp;&nbsp;&nbsp;Accretion of Debt Discount and Loan Origination Fees | 1543896 | 1277827 | 2885912 | 7625298 |
| &nbsp;&nbsp;&nbsp;Change in Fair Value of Derivatives | (3912376) | (14106370) | (3106786) | (16211785) |
| &nbsp;&nbsp;&nbsp;Gain on Extinguishment of Debt |  |  |  | (10233607) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Non-Operating Expenses | 7290458 | (4773954) | 19490722 | (2616752) |
| Loss from Continuing Operations Before Provision for Income Taxes | (14025468) | (16355274) | (32673967) | (42826906) |
| Provision for Income Tax Expense | (1060808) | 8137898 | (6752886) | (11554010) |
| Net Loss from Continuing Operations | (15086276) | (8217376) | (39426853) | (54380916) |
| Net Income (Loss) from Discontinued Operations, Net of Taxes | (2255978) | (12140600) | 26132489 | (26587091) |
| Net Income (Loss) | (17342254) | (20357976) | (13294364) | (80968007) |
| Net Loss Attributable to Non-Controlling Interest | (1134849) | (1331174) | (1247161) | (6611177) |
| **Net Income (Loss) Attributable to Shareholders of MedMen Enterprises Inc.** | $**(16207405)** | $**(19026802)** | $**(12047203)** | $**(74356830)** |
| **Earnings (Loss) Per Share - Basic and Diluted:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;**From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc.** | $**(0.01)** | $**(0.01)** | $**(0.03)** | $**(0.05)** |
| &nbsp;&nbsp;&nbsp;**From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc.** | $**(0.00)** | $**(0.01)** | $**0.01** | $**(0.02)** |
| &nbsp;&nbsp;&nbsp;**Weighted-Average Shares Outstanding - Basic** | **1301874615** | **1198515279** | **1301767158** | **1070605666** |
| &nbsp;&nbsp;&nbsp;**Weighted-Average Shares Outstanding - Diluted** | **1301874615** | **1198515279** | **4845052067** | **1070605666** |

---

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements (Unaudited).

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**MEDMEN ENTERPRISES INC.**<br>**Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited)**<br>*(Amounts Expressed in United States Dollars, Except for Share Data)*<br>

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **For the Six Months Ended December 24, 2022** | **For the Six Months Ended December 24, 2022** | **For the Six Months Ended December 24, 2022** | **For the Six Months Ended December 24, 2022** | **For the Six Months Ended December 24, 2022** | **For the Six Months Ended December 24, 2022** | **For the Six Months Ended December 24, 2022** |
| | ***Units*** | **$ Amount** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Deficit** | **TOTAL EQUITY<br>ATTRIBUTABLE<br>TO<br>SHAREHOLDERS<br>OF MEDMEN** | **Non-<br>Controlling<br>Interest** | **TOTAL<br>SHAREHOLDERS'<br>DEFICIENCY** |
| | ***Subordinate<br>Voting<br>Shares*** | **Subordinate<br>Voting<br>Shares** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Deficit** | **TOTAL EQUITY<br>ATTRIBUTABLE<br>TO<br>SHAREHOLDERS<br>OF MEDMEN** | **Non-<br>Controlling<br>Interest** | **TOTAL<br>SHAREHOLDERS'<br>DEFICIENCY** |
| **Balance as of June 25, 2022** | ***1301423950*** | $**—** | $**1057228873** | $**(901758875)** | $**155469998** | $**(473982734)** | $**(318512736)** |
| &nbsp;&nbsp;&nbsp;Net Income (Loss) | *—* |  |  | 4160212 | 4160212 | (112312) | 4047901 |
| &nbsp;&nbsp;&nbsp;Controlling Interest Equity Transactions |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Partner Contributions | *—* |  |  | 37561 | 37561 |  | 37561 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Redemption of MedMen Corp Redeemable Shares | *259814* |  | 15318 | (15318) |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-Based Compensation | *—* |  | 863685 |  | 863685 |  | 863685 |
| **Balance as of September 24, 2022** | ***1301683764*** | **—** | $**1058107876** | $**(897576420)** | $**160531456** | $**(474095046)** | $**(313563590)** |
| &nbsp;&nbsp;&nbsp;Net Income (Loss) | *—* |  |  | (16207405) | (16207405) | (1134849) | (17342254) |
| &nbsp;&nbsp;&nbsp;Controlling Interest Equity Transactions |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Partner Contributions | *—* |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Redemption of MedMen Corp Redeemable Shares | *445320* |  | 15079 | (15079) |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-Based Compensation | *—* | *—* | 2113676 | *—* | 2113676 | *—* | 2113676 |
| **Balance as of December 24, 2022** | ***1302129084*** | $**—** | $**1060236631** | $**(913798904)** | $**146437727** | $**(475229895)** | $**(328792168)** |

---

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements (Unaudited).

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**MEDMEN ENTERPRISES INC.**<br>**Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited)**<br>*(Amounts Expressed in United States Dollars, Except for Share Data)*<br>

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **For the Six Months Ended December 25, 2021** | **For the Six Months Ended December 25, 2021** | **For the Six Months Ended December 25, 2021** | **For the Six Months Ended December 25, 2021** | **For the Six Months Ended December 25, 2021** | **For the Six Months Ended December 25, 2021** | **For the Six Months Ended December 25, 2021** |
| | ***Units*** | **$ Amount** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Deficit** | **TOTAL EQUITY<br>ATTRIBUTABLE<br>TO<br>SHAREHOLDERS<br>OF MEDMEN** | **Non-<br>Controlling<br>Interest** | **TOTAL<br>SHAREHOLDERS'<br>DEFICIENCY** |
| | ***Subordinate<br>Voting<br>Shares*** | **Subordinate<br>Voting<br>Shares** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Deficit** | **TOTAL EQUITY<br>ATTRIBUTABLE<br>TO<br>SHAREHOLDERS<br>OF MEDMEN** | **Non-<br>Controlling<br>Interest** | **TOTAL<br>SHAREHOLDERS'<br>DEFICIENCY** |
| **BALANCE AS OF JUNE 27, 2021** | ***726866374*** | $**—** | $**908992686** | $**(717232706)** | $**191759980** | $**(445393599)** | $**(253633619)** |
| &nbsp;&nbsp;&nbsp;Net Loss | *—* |  |  | (55330028) | (55330028) | (5280003) | (60610031) |
| &nbsp;&nbsp;&nbsp;Controlling Interest Equity Transactions |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares Issued for Cash, Net of Fees | *406249973* |  | 73393745 |  | 73393745 |  | 73393745 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares Issued to Settle Debt and Accrued Interest | *20833333* |  | 4030000 |  | 4030000 |  | 4030000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares Issued to Settle Accounts Payable and Liabilities | *4182730* |  | 700000 |  | 700000 |  | 700000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity Component of Debt - New and Amended | *0* |  | 41388048 |  | 41388048 |  | 41388048 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Redemption of MedMen Corp Redeemable Shares | *4054278* |  | 1121441 | 374701 | 1496142 | (1496142) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares Issued for Vested Restricted Stock Units and Cashless Exercise of Options | *8473868* |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares Issued for Exercise of Warrants | *8807605* |  | 1273679 |  | 1273679 |  | 1273679 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares Issued for Conversion of Debt | *16014665* |  | 2371100 |  | 2371100 |  | 2371100 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Grants for Compensation | *1455415* |  | 1421400 |  | 1421400 |  | 1421400 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred Tax Impact On Conversion Feature | *—* |  | (13057730) |  | (13057730) |  | (13057730) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-Based Compensation | *—* |  | 1682677 |  | 1682677 |  | 1682677 |
| **BALANCE AS OF SEPTEMBER 25, 2021** | ***1196938241*** | $**—** | $**1023317046** | $**(772188033)** | $**251129013** | $**(452169744)** | $**(201040731)** |
| &nbsp;&nbsp;&nbsp;Net Loss | *—* |  |  | (19026802) | (19026802) | (1331174) | (20357976) |
| &nbsp;&nbsp;&nbsp;Controlling Interest Equity Transactions |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares Issued for Cash, Net of Fees |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares Issued to Settle Debt and Accrued Interest |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares Issued to Settle Accounts Payable and Liabilities | 98118 |  | 15000 |  | 15000 |  | 15000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity Component of Debt - New and Amended |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Redemption of MedMen Corp Redeemable Shares | 84605 |  | 18627 | 6835 | 25462 | (25462) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares Issued for Vested Restricted Stock Units and Cashless Exercise of Options | 2283972 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares Issued for Exercise of Warrants |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares Issued for Conversion of Debt |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Grants for Compensation | 714356 |  | 207494 |  | 207494 |  | 207494 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred Tax Impact On Conversion Feature |  |  | 1345580 |  | 1345580 |  | 1345580 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-Based Compensation |  |  | 500612 |  | 500612 |  | 500612 |
| **BALANCE AS OF DECEMBER 25, 2021** | ***1200119292*** | $**—** | $**1025404359** | $**(791208000)** | $**234196359** | $**(453526380)** | $**(219330021)** |

---

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements (Unaudited).

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**MEDMEN ENTERPRISES INC.**<br>**Condensed Consolidated Statements of Cash Flows (Unaudited)**<br>*(Amounts Expressed in United States Dollars*<br>

---

| | | |
|:---|:---|:---|
| | **Six Months Ended** | **Six Months Ended** |
| | **December 24,<br>2022** | **December 25,<br>2021** |
| **CASH FLOWS FROM OPERATING ACTIVITIES:** | | |
| &nbsp;&nbsp;Net Loss from Continuing Operations | $(39426853) | $(54380916) |
| &nbsp;&nbsp;Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred Tax Expense |  | (9365019) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and Amortization | 7471055 | 13121707 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Cash Operating Lease Costs | 6200503 | 8854752 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accretion of Debt Discount and Loan Origination Fees | 2885912 | 7625298 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on Disposals of Assets | 1358820 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on Lease Terminations | (3464947) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accretion of Deferred Gain on Sale of Property | (236095) | (283314) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment of Assets | 6716906 | 435241 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Realized and Unrealized Changes in Fair Value of Contingent Consideration | 863856 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in Fair Value of Derivative Liabilities | (3106786) | (16211785) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on Extinguishment of Debt |  | (10233610) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-Based Compensation | 2977361 | 3812183 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest Capitalized to Senior Secured Convertible Debt and Notes Payable | 12319509 | 13008234 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest Capitalized to Finance Lease Liabilities | 969427 | 777564 |
| &nbsp;&nbsp;Changes in Operating Assets and Liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts Receivable and Prepaid Expenses | 5057758 | (1830219) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | (3664591) | (3139817) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Current Assets | (412535) | 321953 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Assets | 534846 | 479019 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts Payable and Accrued Liabilities | 7659848 | 3218996 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest Payments on Finance Leases | (3639574) | (3510293) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash Payments - Operating Lease Liabilities | (1501594) | (5777739) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income Taxes Payable | 12072079 | 17776242 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Current Liabilities | (976314) | (1282468) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**NET CASH PROVIDED BY (USED IN) CONTINUED OPERATING ACTIVITIES** | **10658591** | **(36583991)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Cash Used in Discontinued Operating Activities** | (18992355) | (13314891) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**NET CASH USED IN OPERATING ACTIVITIES** | **(8333764)** | **(49898882)** |
| **CASH FLOWS FROM INVESTING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;Purchases of Property and Equipment | (5974346) | (3974462) |
| &nbsp;&nbsp;Additions to Intangible Assets | (30999) | (486759) |
| &nbsp;&nbsp;Proceeds from the Sale of Assets Held for Sale | 51500000 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**NET CASH PROVIDED BY (USED IN) CONTINUED INVESTING ACTIVITIES** | **45494655** | **(4461221)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Cash Used in Discontinued Investing Activities** |  | (3107056) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES** | **45494655** | **(7568277)** |
| **CASH FLOWS FROM FINANCING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;Issuance of Subordinate Voting Shares for Cash |  | 95000000 |
| &nbsp;&nbsp;Payment of Stock Issuance Costs Relating to Private Placement |  | (5352505) |
| &nbsp;&nbsp;Exercise of Warrants for Cash |  | 1273679 |
| &nbsp;&nbsp;Payment of Debt Issuance Costs Relating to Senior Secured Convertible Credit Facility |  | (2608964) |
| &nbsp;&nbsp;Proceeds from Issuance of Notes Payable |  | 5000000 |
| &nbsp;&nbsp;Principal Repayments of Notes Payable | (32388433) | (152887) |
| &nbsp;&nbsp;Principal Repayments of Finance Lease Liability | (666) | (959) |
| &nbsp;&nbsp;Distributions - Non-Controlling Interest | 37561 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES** | **(32351538)** | **93158364** |
| **NET INCREASE IN CASH AND CASH EQUIVALENTS** | **4809353** | **35691206** |
| Cash Included in Assets Held for Sale |  | (275178) |
| Cash and Cash Equivalents, Beginning of Period | 10795999 | 11575868 |
| **CASH AND CASH EQUIVALENTS, END OF PERIOD** | $**15605352** | $**46991896** |

---

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements (Unaudited).

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**MEDMEN ENTERPRISES INC.**<br>**Condensed Consolidated Statements of Cash Flows (Unaudited)**<br>*(Amounts Expressed in United States Dollars)*<br>

---

| | | |
|:---|:---|:---|
| | **Six Months Ended** | **Six Months Ended** |
| | **December 24,<br>2022** | **December 25,<br>2021** |
| **SUPPLEMENTAL DISCLOSURE FOR CASH FLOW INFORMATION** | | |
| &nbsp;&nbsp;&nbsp;Cash Paid for Interest | $5078605 | $1940280 |
| &nbsp;&nbsp;&nbsp;Non-Cash Investing and Financing Activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net Assets Transferred to Held for Sale |  | 4476993 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Redemption of MedMen Corp Redeemable Shares | 705134 | 1521604 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivative Liability Incurred on Convertible Facility and Equity Financing | 805590 | 30500000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conversion of Convertible Debentures |  | 2371100 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares Issued to Settle Debt and Lender Fees |  | 4030000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares Issued to Settle Accounts Payable and Liabilities |  | 715000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity Component of Debt - New and Amended |  | 41388047 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred Tax Impact on Conversion Feature |  | 11712150 |

---

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements (Unaudited).

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**MEDMEN ENTERPRISES INC.**<br>**Notes to Condensed Consolidated Financial Statements (Unaudited)**<br>**Three and Six Months Ended December 24, 2022 and December 25, 2021**<br>*(Amounts Expressed in United States Dollars, Except for Share and Per Share Data)*<br>

**1.** **NATURE OF OPERATIONS**

MedMen Enterprises Inc. and its subsidiaries over which the company has control (collectively, "MedMen", the "Company", "we" or "us") is a premier cannabis retailer based in the U.S. with an operational footprint in California, Nevada, Illinois, Arizona, Massachusetts, and New York. MedMen offers a robust selection of high-quality products, including MedMen-owned brands – MedMen Red and LuxLyte – through its premium retail stores, proprietary delivery service, as well as curbside and in-store pick up. MedMen Buds provides exclusive access to promotions, product drops and content.

As of December 24, 2022, the Company operates 23 store locations across California (13), Nevada (3), Illinois (1), Arizona (1), Massachusetts (1), and New York (4). The Company continues to market its assets in New York and thus classifies all assets and liabilities and profit or loss allocable to its operations in the state of New York as discontinued operations. In August 2022, the Company completed the sale of its operations in the state of Florida of which all assets and liabilities and profit or loss allocable to Florida were classified as discontinued operations until the day of sale, on August 22, 2022. Subsequent to August 22, 2022, the remaining post-acquisition assets and liabilities, which is primarily comprised of a current receivable for the portion of the sales proceeds due to us in March 2023, and profit or loss allocable to Florida have been reclassified as continuing operations.

**2.** **SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

***Basis of Preparation***

The accompanying Condensed Consolidated Financial Statements have been prepared on a going concern basis in accordance with generally accepted accounting principles in the United States of America ("GAAP"), which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and in accordance with the rules and regulations of the United States Securities and Exchange Commission ("SEC") for interim financial information. The Condensed Consolidated Financial Statements include the accounts of MedMen Enterprises, its subsidiaries and variable interest entities ("VIEs") where the Company is considered the primary beneficiary, if any, after elimination of intercompany accounts and transactions. Investments in entities in which the Company has significant influence, but less than a controlling financial interest, are accounted for using the equity method.

In the opinion of management, all adjustments considered necessary for a fair presentation of the consolidated financial position of the Company as of and for the interim periods presented have been included. The accompanying Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to our ability to continue as a going concern.

The accompanying Condensed Consolidated Financial Statements do not include all of the information required for full annual financial statements. Accordingly, certain information, footnotes and disclosures normally included in the annual financial statements have been condensed or omitted in accordance with SEC rules for interim financial information. The financial data presented herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in the Company's Annual Report on Form 10-K for the year ended June 25, 2022, as filed with the Securities and Exchange Commission on September 9, 2022 (the "2022 Form 10-K").

***Going Concern*** 

As of December 24, 2022, the Company had cash and cash equivalents of $15,605,362 and working capital deficit of $137,433,003. The Company has incurred net losses from continuing operations of $15,086,276 and $39,426,853 for the three and six months ended December 24, 2022, respectively. The conditions described above raise substantial doubt with respect to the Company's ability to meet its obligations for at least one year from the issuance of these Condensed Consolidated Financial Statements, and therefore, to continue as a going concern.

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

The Company plans to continue to fund its operations through the implementation and expansion of its cost savings plan, and various strategic actions, including the successful negotiations of lower costs of occupancy with its master lease landlord and other landlords, divestiture of non-core assets including but not limited to the current asset group held for sale, New York, as well continuing its on-going revenue and vendor strategy of market expansion and retail revenue and gross margin growth. The Company also needs to obtain an extension or a refinancing of its debt-in-default with the secured senior lender. The annual operating plan for fiscal year 2023 estimates the Company will be able to manage ongoing operations. However, its cash needs are significant and not achievable with the current cash flow from operations. If the above strategic actions, for any reason, are inaccessible, it will have a significantly negative effect on the Company's financial condition. Additionally, management expects to continue to manage the Company's operating expenses and reduce its projected cash requirements through reduction of its expenses by delaying new store development, permanently or temporarily closing stores that are deemed to be performing below expectations, and/or implementing other restructuring activities. Furthermore, COVID-19 and the impact the global pandemic on the broader retail environment could also have a significant impact on the Company's financial position, results of operations, equity and or its access to capital and future financing.

***COVID-19***

In response to the COVID-19 pandemic, governmental authorities have enacted and implemented various recommendations and safety measures in an attempt to limit the spread and magnitude of the pandemic. The Company is continuously addressing the effects of the COVID-19 pandemic, a discussion of which is available in Item 1A "*Risk Factors*" of the 2022 Form 10-K. The company's operating results continue to be impacted by the COVID-19 pandemic. The overall impact on our business continues to depend on the length of time that the pandemic continues, the impact on consumer purchasing behavior, macro-economic factors such as inflation, and the extent to which it affects our ability to raise capital, and the effect of governmental regulations imposed in response to the pandemic, which all remain uncertain at this time. The Company will continue to implement and evaluate actions to strengthen our financial position and support the continuity of our business and operations.

***Basis of Consolidation***

Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in the Consolidated Financial Statements from the date that control commences until the date that control ceases. With the exception of MME Florida, LLC, which the Company disposed on August 22, 2022, the list of the Company's subsidiaries included in the Company's 2022 Form 10-K remain complete as of December 24, 2022.

***Significant Accounting Policies***

The significant accounting policies and critical estimates applied by the Company in these Condensed Consolidated Financial Statements are the same as those applied in the Company's audited Consolidated Financial Statements and accompanying notes included in the Company's 2022 Form 10-K, unless otherwise disclosed in these accompanying notes to the Condensed Consolidated Financial Statements for the interim period ended December 24, 2022.

***Earnings (Loss) per Share***

The Company calculates basic loss per share by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is determined by adjusting profit or loss attributable to common shareholders and the weighted-average number of common shares outstanding, for the effects of all dilutive potential common shares, which comprise convertible debentures, restricted stock units, warrants and stock options issued.

***Reclassifications***

Certain amounts reported in the Condensed Consolidated Financial Statements as of June 25, 2022 have non-material corrections and reclassified in order to conform to the current reporting period presentation.

In the Note related to Property and Equipment, the Company reclassified $940,000 to increase leasehold improvements and decrease furniture and fixtures. In the Note related to Intangibles, the Company reclassified $1,440,000 and $964,000 to decrease customer relationships and management agreements, along with the related accumulated amortization.

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

In the Condensed Consolidated Balance Sheet, the Company reclassified $3,662,000 between non-controlling interest and accumulated deficit. In addition, the Company reclassified $6,825,000 to decrease its short-term operating lease liabilities and increase its long-term operating lease liabilities.

There was no change to total current assets, total assets, total liabilities, total shareholders' equity or cash flows as a result of these reclassifications and non-material corrections.

***Recently Adopted Accounting Standards***

In May 2021, the FASB issued Accounting Standards Update ("ASU") 2021-04, "*Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)*" ("ASU 2021-04"), which amends existing guidance for earnings per share ("EPS") in accordance with Topic 260. ASU 2021-04 is effective prospectively for fiscal years beginning after December 15, 2021. The Company adopted ASU 2021-04 on June 26, 2022. The adoption of the standard did not have a material impact on the Company's Condensed Consolidated Financial Statements.

***Recently Issued Accounting Standards***

In March 2020, the FASB issued ASU 2020-04, "*Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting*" ("ASU 2020-04"), provides optional expedients and exceptions for applying GAAP to debt instruments, derivatives, and other contracts that reference London Interbank Offered Rate ("LIBOR") or other reference rates expected to be discontinued as a result of reference rate reform. This guidance is optional and may be elected through December 31, 2022 using a prospective application on all eligible contract modifications. ASU 2020-04 provides optional expedients and exceptions for applying GAAP to instruments affected by reference rate reform if certain criteria are met. The Company did not modify any material contracts due to reference rate reform during the nine months ended September 30, 2022. The Company is currently evaluating the adoption date and impact, if any, adoption will have on its financial position and results of operations.

In September 2022, the FASB issued ASU 2022-04, "*Liabilities – Supplier Finance Programs (Subtopic 405-50)*" ("ASU 2022-04"), which is intended to enhance transparency with supplier finance programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Adoption is applied on a retrospective approach. The Company is currently evaluating the adoption date and impact, if any, adoption will have on its financial position and results of operations.

**3.** **INVENTORY**

The following table provides a summary of total Inventory as of December 24, 2022 and June 25, 2022:

---

| | | |
|:---|:---|:---|
| | **December 24,<br>2022** | **June 25,<br>2022** |
| Raw Materials | $736389 | $521777 |
| Work-in-Process | 956705 | 671541 |
| Finished Goods | 11982228 | 8817413 |
| **Total Inventory** | $**13675322** | $**10010731** |

---

During the six months ended December 24, 2022 and December 25, 2021, the Company recognized impairment of nil and $900,000 respectively, to write down inventory to its net realizable value. The Company did not recognize any impairment of inventory during the three months ended December 24, 2022 and December 25, 2021.

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**4.** **ASSETS HELD FOR SALE**

A reconciliation of our assets held for sale is as follows:

---

| | |
|:---|:---|
| | **Discontinued Operations & Other Assets** |
| **Balance as of June 25, 2022** | $**123158751** |
| Ongoing Activities | (12547238) |
| Proceeds from Sale <sup>(1)</sup> | (67000000) |
| **Balance as of December 24, 2022** | **43611513** |

---

_____________________________________

*(1)See "Note 22 – Discontinued Operations" for further information.*

**5.** **PROPERTY AND EQUIPMENT.**

As of December 24, 2022 and June 25, 2022, property and equipment consists of the following:

---

| | | |
|:---|:---|:---|
| | **December 24,<br>2022** | **June 25,<br>2022** |
| Land and Buildings | $29933999 | $29933999 |
| Capital Leases | 5318516 | 5315625 |
| Furniture and Fixtures | 8651132 | 8776994 |
| Leasehold Improvements | 33625888 | 33069524 |
| Equipment and Software | 15972636 | 16897649 |
| Construction in Progress | 4169772 | 6828923 |
| **Total Property and Equipment** | 97671943 | 100822714 |
| Less Accumulated Depreciation | (40026614) | (36714922) |
| **Property and Equipment, Net** | $**57645329** | $**64107792** |

---

Depreciation expense related to continuing operations for three months ended December 24, 2022 and December 25, 2021 was $3,499,585 and $6,864,790, respectively. Depreciation expense related to continuing operations for six months ended December 24, 2022 and December 25, 2021 was $7,471,055 and $13,121,707, respectively.

The amount of depreciation recognized for capital leases during the three months ended December 24, 2022 and December 25, 2021 was $267,312. The amount of depreciation recognized for capital leases during the six months ended December 24, 2022 and December 25, 2021 was $534,624. see *"Note 9 – Leases"* for further information.

Borrowing costs were not capitalized as there were no active construction projects in progress during the three and six months ended December 24, 2022. During the three and six months ended December 25, 2021, borrowing costs totaling $375,241 were capitalized using an average capitalization rate of 11.95%.

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**6.** **INTANGIBLE ASSETS**

As of December 24, 2022 and June 25, 2022, intangible assets consist of the following:

---

| | | |
|:---|:---|:---|
| | **December 24,<br>2022** | **June 25,<br>2022** |
| Dispensary Licenses | $40814762 | $49253452 |
| Customer Relationships | 16409600 | 16409600 |
| Capitalized Software | 7413470 | 7413470 |
| Intellectual Property | 12455287 | 4016597 |
| **Total Intangible Assets** | $**77093119** | $**77093119** |
| Dispensary Licenses | $(18084368) | $(16876912) |
| Customer Relationships | (15378567) | (15870284) |
| Capitalized Software | (4824287) | (4413974) |
| Intellectual Property | (6152763) | (4185835) |
| Less Accumulated Amortization | (44439985) | (41347005) |
| **Intangible Assets, Net** | $**32653134** | $**35746114** |

---

The Company recorded amortization expense related to continuing operations for the three months ended December 24, 2022 and December 25, 2021 of $1,410,858 and $3,206,091, respectively and amortization expense related to continuing operations for the six months ended December 24, 2022 and December 25, 2021 of $3,123,979 and $6,431,928, respectively.

**7.** **ACCOUNTS PAYABLE AND ACCRUED LIABILITIES**

As of December 24, 2022 and June 25, 2022, accounts payable and accrued liabilities consist of the following:

---

| | | |
|:---|:---|:---|
| | **December 24,<br>2022** | **June 25,<br>2022** |
| Accounts Payable | $19663409 | $14627746 |
| Accrued Liabilities | 9862983 | 9464567 |
| Accrued Inventory | 6397508 | 5868831 |
| Accrued Payroll | 1405253 | 1682517 |
| Local & State Taxes Payable | 5030310 | 6695532 |
| Deferred Gain on Sale of Assets | 566627 | 566627 |
| **Total Accounts Payable and Accrued Liabilities** | $**42926090** | $**38905820** |

---

**8.** **DERIVATIVE LIABILITIES**

A reconciliation of the beginning and ending balance of derivative liabilities and change in fair value of derivative liabilities for the three and six months ended December 24, 2022 is as follows:

---

| | |
|:---|:---|
| | **TOTAL** |
| **Balance as of June 25, 2022** | $6749563 |
| Change in Fair Value of Derivative Liabilities | (3106786) |
| **Balance as of December 24, 2022** | $**3642777** |

---

On August 17, 2021, in connection with the amended and restated senior secured convertible credit facility (the Sixth Amendment"), the Company provided the note holders top-up and preemptive rights which were bifurcated from the

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

related notes and classified as a derivative due to the variability of the number and price of shares issuable under these rights. See "*Note 11 – Senior Secured Convertible Credit Facility"* for further information.

The fair value of the top-up provision in connection with Sixth Amendment of the Convertible Facility was determined using the Black-Scholes simulation model based on Level 3 inputs on the fair value hierarchy. The following assumptions were used at December 24, 2022:

---

| | |
|:---|:---|
| | **Top-Up<br>Provision** |
| Average Stock Price | $0.02 |
| Weighted-Average Probability | 50.00% |
| Term (in Years) | 5 |
| Expected Stock Price Volatility | 121.15% |

---

The following are the warrants issued related to the equity financing transactions that were accounted for as derivative liabilities:

---

| | | | |
|:---|:---|:---|:---|
| | **Number of<br>Warrants** | **Exercise<br>Price (C$)** | **Expiration<br>Date** |
| March 2021 Private Placement <sup>(1)</sup> | 50000000 | $0.50 | March 27, 2024 |
|  | **50000000** |  |  |

---

_____________________________________

*(1)See "Note 12 – Shareholders' Equity" for further information.* 

The fair value of the March 2021 private placement warrants was measured based on Level 3 inputs on the fair value hierarchy using the Black-Scholes Option pricing model using the following variables:

---

| | |
|:---|:---|
| Expected Stock Price Volatility | 161.95% |
| Risk-Free Annual Interest Rate | 2.35% |
| Expected Life (in Years) | 0.25 |
| Share Price | $0.02 |
| Exercise Price | $0.37 |

---

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**9.** **LEASES**

The Company has various operating and finance leases for land, buildings, equipment and other assets that are used for corporate purposes as well as for the production and sale of cannabis products. These leases are subject to covenants and restrictions standard to the industry in which the Company operates.

The below are the details of the lease cost and other disclosures regarding the Company's leases for the three months ended December 24, 2022 and June 25, 2022:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 24,<br>2022** | **December 25,<br>2021** | **December 24,<br>2022** | **December 25,<br>2021** |
| Finance Lease Cost: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Amortization of Finance Lease Right-of-Use Assets | $267312 | $251221 | $534624 | $534627 |
| &nbsp;&nbsp;&nbsp;Interest on Lease Liabilities | 1835068 | 1725752 | 3639574 | 3510293 |
| Operating Lease Cost | 2746638 | 4412675 | 6200503 | 8854752 |
| **Total Lease Expenses** | $**4849018** | $**6389648** | $**10374701** | $**12899672** |
| Sublease Income <sup>(1)</sup> | $(1521651) | $(1444234) | $(3043302) | $(1444234) |
| Cash Paid for Amounts Included in the Measurement of Lease Liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financing Cash Flows from Finance Leases | $(1818) | $— | $666 | $959 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating Cash Flows from Operating Leases | $474802 | $2298848 | $1501594 | $5777739 |

---

_____________________________________

*(1)See "Note 16 – Other Operating Income" for further information.*

The weighted-average remaining lease term and discount rate related to the Company's finance and operating lease liabilities as of December 24, 2022 and June 25, 2022, is as follows:

---

| | | |
|:---|:---|:---|
| | **December 24,<br>2022** | **June 25,<br>2022** |
| Weighted-Average Remaining Lease Term (Years) - Finance Leases | 46 | 46 |
| Weighted-Average Remaining Lease Term (Years) - Operating Leases | 7 | 8 |
| Weighted-Average Discount Rate - Finance Leases | 24.81% | 24.33% |
| Weighted-Average Discount Rate - Operating Leases | 16.66% | 18.70% |

---

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

Future lease payments under non-cancellable operating leases and finance leases as of December 24, 2022 are as follows:

---

| | | |
|:---|:---|:---|
| **Fiscal Year Ending** | **Operating<br>Leases** | **Finance<br>Leases** |
| &nbsp;&nbsp;July 1, 2023 (remaining) | $4692026 | $2934524 |
| &nbsp;&nbsp;June 29, 2024 | 12931089 | 10961495 |
| &nbsp;&nbsp;June 28, 2025 | 9311213 | 7087736 |
| &nbsp;&nbsp;June 27, 2026 | 9495658 | 7300368 |
| &nbsp;&nbsp;June 26, 2027 | 9466730 | 7519379 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thereafter | 26267466 | 1061283374 |
| Total Lease Payments | 72164182 | 1097086876 |
| Less Interest | (19541732) | (1065503555) |
| **Lease Liability Recognized** | $**52622450** | $**31583321** |

---

The Company entered into a management agreement (the "Management Agreement") with a third party to operate its cultivation facilities in California and Nevada (the "Cultivation Facilities"). On September 30, 2021, the landlord approved the third party to operate the leased facilities which effectuated the Management Agreement. The Management Agreement provides the third party an option to acquire all the assets used in the Cultivation Facilities, including the cannabis licenses and equipment, for $1 (the "Purchase Option"). The fee for the services under the Management Agreement is 100% and 30% of the California and Nevada Cultivation Facilities net revenue, respectively. The term of the Management Agreement remains in effect until the earlier of (a) the closing of any sale pursuant to the Purchase Option and (b) the expiration of the term, as applicable, of the master lease, at which time this Management Agreement shall automatically terminate without any further action of the Parties. As of December 24, 2022, the Management Agreement remains in effect as neither termination condition has occurred. During the three and six months ended December 24, 2022, the Company recorded sublease income under the Management Agreement. See "*Note 16 – Other Operating Income*" for further information.

**10.** **NOTES PAYABLE**

Refer to the 2022 Form 10-K for complete disclosure of current terms of notes payable included in the footnotes of the annual financial statements as of June 25, 2022. There were no amendments during the six months ended December 24, 2022

As of December 24, 2022 and June 25, 2022, notes payable consist of the following:

---

| | | |
|:---|:---|:---|
| | **December 24,<br>2022** | **June 25,<br>2022** |
| Financing liability incurred on various dates between January 2019 through September 2019 with implied interest rates ranging from 0.7% to 17.0% per annum. | $72300000 | $72300000 |
| Non-revolving, senior secured term notes dated between October 1, 2018 and October 30, 2020, issued to accredited investors, which mature on August 1, 2022 and July 31, 2022, and bear interest at a rate of 15.5% and 18.0% per annum. | 66169035 | 97162001 |
| Promissory notes dated November 7, 2018, issued to Lessor for tenant improvements as part of sales and leaseback transactions, which mature on November 7, 2028, bear interest at a rate of 10% per annum and require minimum monthly payments of $15,660 and $18,471. | 2057207 | 2057207 |
| Other | 15691 | 15691 |
| Total Notes Payable | 140541933 | 171534899 |
| Less Unamortized Debt Issuance Costs and Loan Origination Fees | (137478) | (158079) |
| Net Amount | 140404455 | 171376820 |
| Less Current Portion of Notes Payable | (66294249) | (97003922) |
| Notes Payable, Net of Current Portion | $**74110206** | $**74372898** |

---

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

A reconciliation of the beginning and ending balances of notes payable for the six months ended December 24, 2022 is as follows:

---

| | |
|:---|:---|
| | **December 24,<br>2022** |
| Balance at Beginning of Period | $171376820 |
| &nbsp;&nbsp;&nbsp;&nbsp;Paid-In-Kind Interest Capitalized | 1257988 |
| &nbsp;&nbsp;&nbsp;Cash Payments | (32388433) |
| &nbsp;&nbsp;&nbsp;Accretion of Debt Discount | (239953) |
| &nbsp;&nbsp;&nbsp;Accretion of Debt Discount Included in Discontinued Operations | 398032 |
| **Balance at End of Period** | $**140404454** |
| Less Current Portion of Notes Payable | $(66294249) |
| **Notes Payable, Net of Current Portion** | $**74110205** |

---

***Non-Revolving Senior Secured Term Loan Facility*** 

In February 2022, the Company executed the Sixth Modification extending the maturity date of the senior secured term loan facility (the "Facility") with Hankey Capital and Stable Road Capital (the "Lenders") to July 31, 2022 with respect to the Facility, and August 1, 2022 with respect to the incremental term loans (collectively, the "Term Loans"). The Sixth Modification required that the Company make a mandatory prepayment of at least $37,500,000 in the event the sale of certain assets and imposed covenants in regard to strategic actions the Company would have to implement if unable to pay the Term Loans by the extended stated maturity date.

During the six months ended December 24, 2022, in connection with the sale of the Company's Florida-based operations, the Company made a principal repayment of $31,600,000 with proceeds from the sale. An additional $8,500,000 principal repayment will be made in 2023 upon receipt of the final installment payment from the sale of the Company's Florida-based operations. The Facility and Term Loans remain in default as of December 24, 2022 as the principal balance matured on July 31, 2022 and August 1, 2022, respectively. Beginning in December 2022, the interest assessed on the Facility and Term Loans include a default interest rate of 5%. As of December 24, 2022, the Company is in ongoing discussions with the Lenders.

**11.** **SENIOR SECURED CONVERTIBLE CREDIT FACILITY**

Refer to the 2022 Form 10-K for complete disclosure of current terms of the senior secured convertible facility included in the footnotes of the annual financial statements as of June 25, 2022. There were no amendments during the three months ended December 24, 2022.

As of December 24, 2022 and June 25, 2022, senior secured convertible credit facility consists of the following:

---

| | | | |
|:---|:---|:---|:---|
| | **Tranche** | **December 24,<br>2022** | **June 25, 2022** |
| Senior secured convertible notes dated August 17, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. | 1A | $23944485 | $22880556 |
| Senior secured convertible notes dated May 22, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. | 1B | 103124572 | 98542422 |
| Senior secured convertible notes dated July 12, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. | 2 | 33534018 | 32043996 |
| Senior secured convertible notes dated November 27, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. | 3 | 12985058 | 12408091 |

---

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

---

| | | | |
|:---|:---|:---|:---|
| Senior secured convertible notes dated March 27, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. | 4 | 15273641 | 14594985 |
| Amendment fee converted to senior secured convertible notes dated October 29, 2019, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. |  | 24512781 | 23424438 |
| Senior secured convertible notes dated April 24, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. | IA-1 | 3428182 | 3275857 |
| Senior secured convertible notes dated September 14, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. | IA-2 | 6629552 | 6334980 |
| Restatement fee issued in senior secured convertible notes dated March 27, 2020, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. |  | 10348746 | 9888919 |
| Second restatement fee issued in senior secured convertible notes dated July 2, 2020, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. |  | 2292231 | 2190380 |
| Third restatement fee issued in senior secured convertible notes dated January 11, 2021, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. |  | 12893031 | 12320154 |
| Total Drawn on Senior Secured Convertible Credit Facility |  | 248966298 | 237904778 |
| Less Unamortized Debt Discount |  | (102773249) | (105899115) |
| **Senior Secured Convertible Credit Facility, Net** |  | $**146193049** | $**132005663** |

---

A reconciliation of the beginning and ending balances of senior secured convertible credit facility for the six months ended December 24, 2022 is as follows:

---

| | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Tranche 1** | | **Tranche 2** | **Tranche 3** | **Tranche 4** | **Incremental Advance<br>- 1** | **Incremental Advance<br>- 2** | **3rd Advance** | **Amendment <br> Fee Notes** | **Restatement Fee Notes** | | **2nd Restatement Fee<br>Notes** | **TOTAL** |
| **Balance as of June 25, 2022** | $**80178586** | $**—** | $**21218356** | $**8217079** | $**1051827** | $**224585** | $**433598** | $**842981** | $**15512409** | $**2211711** |  | $**2114531** | $**132005663** |
|  |  |  |  |  |  |  |  |  |  | $**—** |  |  |  |
| Paid-In-Kind Interest Capitalized | 5646079 |  | 1490022 | 576967 | 678656 | 152325 | 294572 | 572878 | 1088344 | 459827 |  | 101851 | 11061521 |
| Accretion of Debt Discount | 1954788 |  | 514561 | 199249 |  |  |  |  | 376148 | 73578 |  | 7541 | 3125865 |
| Balance as of December 24, 2022 | $**87779453** |  | $**23222939** | $**8993295** | $**1730483** | $**376910** | $**728170** | $**1415859** | $**16976901** | $**2745116** | $**—** | $**2223923** | $**146193049** |

---

**12.** **SHAREHOLDERS' EQUITY**

***Issued and Outstanding***

A reconciliation of the beginning and ending issued and outstanding shares is as follows:

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

---

| | | | |
|:---|:---|:---|:---|
| | **Subordinate<br>Voting Shares** | **MM CAN USA<br>Class B<br>Redeemable Units** | **MM Enterprises USA<br>Common Units** |
| **Balance as of June 25, 2022** | **1301423950** | **65066106** | **725016** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Redemption of MedMen Corp Redeemable Shares | 259814 | (259814) |  |
| **Balance as of September 24, 2022** | **1301683764** | **64806292** | **725016** |
| &nbsp;&nbsp;&nbsp;Redemption of MedMen Corp Redeemable Shares | 445320 | (445320) |  |
| **Balance as of December 24, 2022** | **1302129084** | **64360972** | **725016** |

---

***Non-Controlling Interests***

Non-controlling interest represents the net assets of the subsidiaries that the holders of the Subordinate Voting Shares do not directly own. The net assets of the non-controlling interest are represented by the holders of MM CAN USA Redeemable Shares and the holders of MM Enterprises USA Common Units. Non-controlling interest also represents the net assets of the entities the Company does not directly own but controls through a management agreement. As of December 24, 2022 and June 25, 2022, the holders of the MM CAN USA Redeemable Shares represent approximately 4.71% and 4.76%, respectively, of the Company and holders of the MM Enterprises USA Common Units represent approximately 0.05% of the Company.

***Variable Interest Entities***

The below information are entities the Company has concluded to be variable interest entities ("VIEs") as the Company possesses the power to direct activities through management services agreements ("MSAs"). Through these MSAs, the Company can significantly impact the VIEs and thus holds a controlling financial interest. The following table represents the summarized financial information about the Company's consolidated VIEs. VIEs include the balances of Venice Caregiver Foundation, Inc., LAX Fund II Group, LLC, and Natures Cure, Inc. This information represents amounts before intercompany eliminations.

As of and for the six months ended December 24, 2022, the balances and activities attributable to the VIEs consist of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Venice Caregivers<br>Foundation, Inc.** | **LAX Fund II Group, LLC** | **Natures Cure, Inc.** | **TOTAL** |
| Current Assets | $1471651 | $— | $27171414 | $28643065 |
| Non-Current Assets | 8482483 | 3011882 | 4874353 | 16368718 |
| **Total Assets** | $**9954134** | $**3011882** | $**32045767** | $**45011783** |
| Current Liabilities | $10984598 | $16687993 | $10031350 | $37703941 |
| Non-Current Liabilities | 6957566 | 1922553 | 1342632 | 10222751 |
| **Total Liabilities** | $**17942164** | $**18610546** | $**11373982** | $**47926692** |
| **Non-Controlling Interest** | $**(7988030)** | $**(15598664)** | $**20671785** | $**(2914909)** |
| **Revenues** | $**3766847** | $**—** | $**6562185** | $**10329032** |
| **Net (Loss) Income Attributable to Non-Controlling Interest** | $**(944589)** | $**(1622510)** | $**1917227** | $**(649872)** |

---

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

As of and for the fiscal year ended June 25, 2022, the balances of the VIEs consists of the following:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Venice Caregivers<br>Foundation, Inc.** | | **LAX Fund II Group, LLC** | | **Natures Cure, Inc.** | | **TOTAL** |
| Current Assets | $1735304 |  | $1067636 |  | $23557168 |  | $26360108 |
| Non-Current Assets | 10073880 |  | 3379412 |  | 4973459 |  | 18426751 |
| **Total Assets** | $**11809184** | $— | $**4447048** | $— | $**28530627** |  | $**44786859** |
| Current Liabilities | $9238460 |  | $16238249 |  | $8433436 |  | $33910145 |
| Non-Current Liabilities | 9614164 |  | 2184953 |  | 1342633 |  | 13141750 |
| **Total Liabilities** | $**18852624** | $**—** | $**18423202** | $**—** | $**9776069** |  | $**47051895** |
| **Non-Controlling Interest** | $**(7043440)** | $**—** | $**(13976154)** | $**—** | $**18754558** | $**—** | $**(2265036)** |
| **Revenues** | $**4815688** |  | $**—** |  | $**8816113** |  | $**13631801** |
| **Net (Loss) Income Attributable to Non-Controlling Interest** | $**(607858)** |  | $**(2206450)** |  | $**3911125** |  | $**1096817** |

---

The net change in the consolidated VIEs and other non-controlling interest are as follows for the six months ended December 24, 2022:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Venice Caregivers<br>Foundation, Inc.** | **LAX Fund II Group, LLC** | **Natures Cure, Inc.** | **Other Non- Controlling<br>Interests** | **TOTAL** |
| **Balance as of June 25, 2022** | $(7043440) | $(13976154) | $18754558 | $(471717698) | $(473982734) |
| Net (Loss) Income | $(944589) | $(1622510) | $1917227 | $(597289) | $(1247161) |
| **Balance as of December 24, 2022** | $**(7988029)** | $**(15598664)** | $**20671785** | $**(472314987)** | $**(475229895)** |

---

**13.** **SHARE-BASED COMPENSATION**

The Company has a stock and equity incentive plan (the "Incentive Plan") under which the Company may issue various types of equity instruments to any employee, officer, consultant, advisor or director. The types of equity instruments issuable under the Incentive Plan encompass, among other things, stock options, stock grants, and restricted stock units (together, "Awards"). Stock based compensation expenses are recorded as a component of general and administrative expenses. The maximum number of Awards that may be issued under the Incentive Plan shall be determined by the Compensation Committee or the Board of Directors in the absence of a Compensation Committee. Any shares subject to an Award under the Incentive Plan that are forfeited, cancelled, expire unexercised, are settled in cash or are used or withheld to satisfy tax withholding obligations, shall again be available for Awards under the Incentive Plan. Vesting of Awards will be determined by the Compensation Committee or Board of Directors in absence of a Compensation Committee. The exercise price for Awards (if applicable) will generally not be less than the fair market value of the Award at the time of grant and will generally expire after 5 or 10 years.

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

A summary of share-based compensation expense for the three and six months ended December 24, 2022 and December 25, 2021 is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 24,<br>2022** | **December 25,<br>2021** | **December 24,<br>2022** | **December 25,<br>2021** |
| Stock Options | $1912792 | $97746 | $2625581 | $1314193 |
| Stock Grants for Compensation |  | 207494 |  | 540827 |
| Restricted Stock Grants | 200884 | 402866 | 351780 | 1957163 |
| **Total Share-Based Compensation** | $**2113676** | $**708106** | $**2977361** | $**3812183** |

---

***Stock Options*** 

A reconciliation of the beginning and ending balance of stock options outstanding is as follows:

---

| | | |
|:---|:---|:---|
| | **Number of<br>Stock Options** | **Weighted-Average<br>Exercise Price** |
| **Outstanding at June 25, 2022** | **8649673** | $**1.35** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Granted | 92382965 | 0.05 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forfeited | (312032) | 3.60 |
| **Outstanding at December 24, 2022** | **100720606** | $**0.15** |
| **Stock Options Exercisable as of December 24, 2022** | **8037095** |  |

---

***Long-Term Incentive Plan ("LTIP") Units and LLC Redeemable Units*** 

A reconciliation of the beginning and ending balances of the LTIP Units and LLC Redeemable Units issued for compensation outstanding is as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **LTIP Units** | **LLC<br>Redeemable<br>Units** | **Weighted<br>Average<br>Grant Date<br>Fair Value** |
| | **Issued and<br>Outstanding** | **LLC<br>Redeemable<br>Units** | **Weighted<br>Average<br>Grant Date<br>Fair Value** |
| **Balance as of June 25, 2022 and December 24, 2022** | **19323878** | **725016** | $**0.52** |

---

***Restricted Stock Units***

A reconciliation of the beginning and ending balance of restricted stock units outstanding is as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Issued and<br>Outstanding** | **Vested** | **Weighted-Average<br>Fair Value** |
| **Balance as of June 25, 2022** | **10998483** | **4030460** | $**0.20** |
| &nbsp;&nbsp;&nbsp;Granted |  |  |  |
| &nbsp;&nbsp;&nbsp;Vested |  | 490661 | 0.21 |
| &nbsp;&nbsp;&nbsp;Forfeited <sup>(1)</sup> | (1813408) |  | (0.22) |
| **Non-vested at December 24, 2022** | **9185075** | **4521121** | $**0.30** |

---

_____________________________________

*(1)Restricted stock units represent units forfeited upon resignation of certain employees prior to their vesting.*

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

***Warrants***

A reconciliation of the beginning and ending balance of warrants outstanding is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Number of Warrants Outstanding** | **Number of Warrants Outstanding** | **Number of Warrants Outstanding** | |
| | **Subordinate<br>Voting Shares** | **MM CAN USA<br>Redeemable Shares** | **TOTAL** |<br>**Weighted-Average<br>Exercise Price** |
| **Balance as of June 25, 2022** | **352704355** | **97430456** | **450134811** | $**0.25** |
| &nbsp;&nbsp;&nbsp;&nbsp;Expired | (6023696) |  | (6023696) | $2.03 |
| **Balance as of December 24, 2022** | **346680659** | **97430456** | **444111115** | $**0.22** |

---

**14.** **LOSS PER SHARE**

The following is a reconciliation for the calculation of basic and diluted loss per share for the three and six months ended December 24, 2022 and December 25, 2021 is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 24,<br>2022** | **December 25,<br>2021** | **December 24,<br>2022** | **December 25,<br>2021** |
| Net Loss from Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc. | $(15086) | $(8217) | $(39427) | $(54381) |
| Net Income (Loss) from Discontinued Operations | (2256) | (12141) | 26132 | (26587) |
| Total Loss | $(17342) | $(20358) | $(13294) | $(80968) |
| Denominator: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted-Average Shares Outstanding - Basic | 1301874615 | 1198515279 | 1301767158 | 1070605666 |
| &nbsp;&nbsp;&nbsp;&nbsp;Dilutive effect of LTIP and LLC Redeemable Units issued for compensation | 19323878 | 19323878 | 19323878 | 19323878 |
| &nbsp;&nbsp;&nbsp;&nbsp;Dilutive effect of restricted stock granted under the Equity Plan | 9185075 | 25673720 | 9185075 | 25673720 |
| &nbsp;&nbsp;&nbsp;&nbsp;Dilutive effect of warrants and top-up warrants | 194720261 | 138498284 | 258878685 | 175668177 |
| &nbsp;&nbsp;&nbsp;&nbsp;Dilutive effect of convertible debentures | 3255897270 | 1007089116 | 3255897270 | 1007089116 |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted-Average Shares Outstanding - Diluted <sup>(1)</sup> | 4781001100 | 2389100278 | 4845052067 | 2298360557 |

---

<sup>(1)</sup> For all periods presented wherein the Company incurred net losses from continuing operations and/or discontinued operations, the calculation of diluted net loss per share gives no consideration to the potentially anti-dilutive securities shown in the above reconciliation, and as such is the same as basic net loss per share.

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**15.** **GENERAL AND ADMINISTRATIVE EXPENSES**

During the three and six months ended December 24, 2022 and December 25, 2021, general and administrative expenses consisted of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 24,<br>2022** | **December 25,<br>2021** | **December 24,<br>2022** | **December 25,<br>2021** |
| Salaries and Benefits | $6536411 | $9991545 | $13468859 | $19903033 |
| Professional Fees | 2137010 | 7815185 | 3509420 | 15245844 |
| Rent | 3021217 | 4712476 | 6649162 | 9467359 |
| Licenses, Fees and Taxes | 1823436 | 1293194 | 3866945 | 3830982 |
| Share-Based Compensation | 2113676 | 722802 | 2977361 | 2370111 |
| Deal Costs |  | 1174357 | 429272 | 2811944 |
| Other General and Administrative | 2709471 | 5583195 | 5551538 | 10312715 |
| **Total General and Administrative Expenses** | $**18341221** | $**31292754** | $**36452557** | $**63941988** |

---

**16.** **OTHER OPERATING (INCOME) EXPENSE**

During the three and six months ended December 24, 2022 and December 25, 2021, other operating (income) expense consisted of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 24,<br>2022** | **December 25,<br>2021** | **December 24,<br>2022** | **December 25,<br>2021** |
| **Other Operating (Income) Expense:** | | | | |
| Loss (Gain) on Disposals of Assets | $1153225 | $(141662) | $1358820 | $(126516) |
| Restructuring and Reorganization Expense |  | 385652 | 423793 | 2764327 |
| Gain on Settlement of Accounts Payable | 215659 |  | 141022 | (177990) |
| (Gain) Loss on Lease Terminations | (1877298) | 173765 | (3464947) | 173765 |
| (Gain) Loss on Disposal of Assets Held for Sale | (112225) |  | 532598 |  |
| Legal Settlements | (3491431) |  | (3491431) |  |
| Other Income | (1522280) | 213216 | (3043918) | 196413 |
| **Total Other Operating (Income) Expense** | $**(5634350)** | $**630971** | $**(7544063)** | $**2829999** |

---

During the three and six months ended December 24, 2022, the Company recorded $1,521,651 and $3,043,302, respectively of sublease income related to the cultivation facilities in California and Nevada as a component of Other Operating Income in the Consolidated Statements of Operations.

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**17.** **PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES**

The following table summarizes the Company's income tax expense and effective tax rates for the three and six months ended December 24, 2022 and December 25, 2021

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 24,<br>2022** | **December 25,<br>2021** | **December 24,<br>2022** | **December 25,<br>2021** |
| Loss from Continuing Operations Before Provision for Income Taxes | $(14025468) | $(16355274) | $(32673967) | $(42826906) |
| Provision for Income Tax Expense | (1060808) | 8137898 | (6752886) | (11554010) |
| Effective Tax Rate | 8% | -50% | 21% | 27% |

---

We have historically calculated the provision for income taxes during interim reporting periods by applying an estimate of the annual effective tax rate ("AETR") for the full fiscal year to "ordinary" income or loss (pre-tax income or loss excluding unusual or infrequently occurring discrete items) for the reporting period. For the three and six months ended December 25, 2021, we determined we could no longer reliably estimate income taxes utilizing an AETR. The AETR estimate is highly sensitive to estimates of ordinary income (loss) and permanent differences such that minor fluctuations in these estimates could result in significant fluctuations of the Company's AETR. Accordingly, we used our actual year-to-date effective tax rate to calculate income taxes for the three and six months ended December 24, 2022.

As the Company operates in the legal cannabis industry, the Company is subject to the limits of IRC Section 280E for U.S. federal, Illinois state, Massachusetts state and New York state income tax purposes under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E. However, the State of California does not conform to IRC Section 280E and, accordingly, the Company deducts all operating expenses on its California Franchise Tax Returns.

The Company has approximately gross $12,230,000 (tax effected $3,240,000) of Canadian non-capital losses and $6,000,000 (tax effected $1,620,000) of share issuance cost 20(1)(e) balance. The loss tax attribute has been determined to be more likely than not that the tax attribute would not yield any tax benefit. As such, the Company has recorded a full valuation allowance against the benefit. Since IRC Section 280E was not applied in the California Franchise Tax Returns, the Company has approximately $22,000,000 of gross California net operating losses which begin expiring in 2033 as of June 25, 2022. The Company has evaluated the realization of its California net operating loss tax attribute and has determined under the more likely than not standard that $217,300,000 will not be realized.

The effective tax rate for the three and six months ended December 24, 2022 is different from the three months ended September 25, 2021, respectively, primarily due to the Company's income and related 280E expenditures. The Company's non-deductible expenses related to IRC Section 280E limitations have remained relatively consistent.

The Company files income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and in Canada. The Company is generally subject to audit by taxing authorities in various U.S., state, and in foreign jurisdictions for fiscal years 2014 through the current fiscal year. As of December 24, 2022, the Company had $18,781,424 of unrecognized tax benefits, all of which would reduce income tax expense and the effective tax rate if recognized. During the three and six months ended December 24, 2022, the Company recognized a net discrete tax expense of $407,993 primarily related on interest of past liabilities. During the next twelve months, the Company does not estimate any material reduction in its unrecognized tax benefits.

**18.** **COMMITMENTS AND CONTINGENCIES**

***Contingencies***

The Company's operations are subject to a variety of local and state regulations. Failure to comply with one or more of these regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations. While management of the Company believes that the Company is in compliance with applicable local

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

and state regulations as of December 24, 2022 and June 25, 2022, marijuana regulations continue to evolve and are subject to differing interpretations. As a result, the Company may be subject to regulatory fines, penalties or restrictions in the future.

***Claims and Litigation***

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. The Company recognizes legal settlement expense when litigation losses related to pending or threatening lawsuits could be reasonably assessed to have resulted in a probable loss to the Company in an amount that can be reasonably estimated. The Company recognizes legal settlement gains when a favorable settlement is awarded to the Company and payment is received. Gain and losses related to claims and litigation are recorded as a component of Other Operating (Income) Expense in the Condensed Consolidated Financial Statements. As of December 24, 2022, there are also no proceedings in which any of the Company's current directors, officers or affiliates is an adverse party to the Company or has a material interest adverse to the Company's interest.

In March 2020, litigation was filed against the Company in the Superior Court of Arizona, Maricopa County, related to a purchase agreement for a previous acquisition. The Superior Court of Arizona, Maricopa County granted summary judgement in favor of the Company on all counts in July 2022. The Company is currently in process of recovering certain fees and costs associated with the lawsuit from the plaintiffs, and the plaintiffs have filed an appeal of the summary judgment decision. The Company believes the likelihood of a loss contingency is neither probable nor estimable. As such, no amount has been accrued in these financial statements.

In April 2020, a complaint was filed against the Company in Los Angeles Superior Court related to a contemplated acquisition in which the plaintiffs are seeking damages for alleged breach of contract and breach of implied covenant of good faith and fair dealing seeking declaratory relief and specific performance. The Company filed counterclaims including for breach of contract, breach of promissory note, unjust enrichment and declaratory relief. After the end of the quarter ending December 24, 2022, the parties reached a tentative agreement to resolve the litigation; however, the probable loss to the Company cannot be reasonably estimated. As such, no amount has been accrued in these financial statements.

In November 2020, entities affiliated with former officers of the Company initiated arbitration against a subsidiary of the Company in Los Angeles, California asserting breach of contract, breach of the implied covenant of good faith and fair dealing, fraud, and unjust enrichment. The claimants are generally seeking damages and compensatory damages according to proof, including lost earnings and other benefits, past and future, interest on lost earnings and benefits, reasonable attorney's fees, and such other and further relief as the court deems proper. The Company asserted counterclaims, including for breach of the same management agreements. The arbitration hearing has been rescheduled and the matter is being disputed. The litigation remains at an early stage and the likelihood of a loss contingency is remote. As such, no amount has been accrued in these financial statements.

In October 2021, a suit for premises liability and negligence seeking unspecified damages for pain and suffering, disability, mental and emotional distress, and loss of earnings was filed against the Company in Los Angeles Superior Court. The matter is in the process of being litigated. The Company believes the likelihood of loss is remote. As such, no amount has been accrued in these financial statements.

In July 2022, a complaint was filed in Los Angeles Superior Court by Baker & McKenzie LLP, a former law firm to the Company, seeking in excess of $600,000 in legal fees plus accrued interest. The Company has filed a counterclaim against Baker & McKenzie claiming overbilling on total invoices propounded by the law firm to the Company exceeding $18,500,000. The litigation remains at an early stage and the likelihood of a loss contingency is remote. As such, no amount has been accrued in these financial statements

The Company is the defendant in several complaints filed by various of its landlords seeking rents and damages under lease arrangements. First, in 2020 a complaint was filed in Cook County Circuit Court, Illinois against the Company by a landlord claiming the Company had failed to meet its obligations to apply effort to obtain a retail cannabis license at a property, for which the landlord is seeking rents and damages. Plaintiff has filed a motion for summary judgment which remains pending. If the litigation is not settled or resolved, trial will likely take place during the fiscal year ended 2023 or possibly the fiscal year ended 2024. This matter is preliminary and the Company believes the likelihood of loss is remote. As such, no amount has been accrued in these financial statements. Second, in July 2022, a complaint was filed against the Company in the United States District Court for the Southern District of New York by a landlord seeking damages under a lease on real estate located in Illinois. The Company filed an answer to the complaint arguing that the subject matter of the

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

case was not appropriate for determination by a federal court in New York. The court thereafter permitted the action to be dismissed without prejudice, after which the plaintiff refiled the case in California against the Company as guarantor of the lease. The matter is in the process of being litigated in the Los Angeles Superior Court. The Company believes the likelihood of loss is remote. As such, no amount has been accrued in these financial statements. Third, in June 2022, a complaint was filed against the Company by the Company's landlord at its cultivation center in Utica, New York, related to an agreement to purchase land next to the cultivation center, which land was also owned by the landlord. Plaintiff sought to enforce a land purchase agreement and is seeking damages. The Company settled this dispute during the quarter ending December 24, 2022 in the amount of $350,000. In April 2022, the landlord at the Company's dispensary location in Tampa, Florida, filed suit seeking damages under a lease, shortly after which the Company announced its plans to sell its Florida operations. The Company retained this lease and the associated litigation following the sale of its Florida operations. The litigation is at an early stage and the likelihood of a loss contingency is remote. As such, no amount has been accrued in these financial statements.

**19.** **RELATED PARTY TRANSACTIONS**

The Company's Board of Directors each receive quarterly fees of $200,000 of which one-third is paid in cash and two-thirds is paid in Class B Subordinate Voting Shares.

**20.** **SEGMENT INFORMATION**

The Company currently operates in one segment, the production and sale of cannabis products, which is how the Company's Chief Operating Decision Maker manages the business and makes operating decisions. The Company's cultivation operations are not considered significant to the overall operations of the Company. Intercompany sales and transactions are eliminated in consolidation.

**21.** **REVENUE**

While the Company operates in one segment as disclosed in "*Note 20 – Segment Information*", the Company is disaggregating its revenue by geographical region in accordance with ASC 606, "*Revenue from Contracts with Customers*". Revenue by state for the periods presented are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 24,<br>2022** | **December 25,<br>2021** | **December 24,<br>2022** | **December 25,<br>2021** |
| &nbsp;&nbsp;&nbsp;California | $19575393 | $23368439 | $39504378 | $47994994 |
| &nbsp;&nbsp;&nbsp;Nevada | 2812902 | 3855371 | 5810371 | 7934522 |
| &nbsp;&nbsp;&nbsp;Illinois | 3082089 | 4104970 | 6624159 | 8433572 |
| &nbsp;&nbsp;&nbsp;Arizona | 3343592 | 4173609 | 6138238 | 7875206 |
| &nbsp;&nbsp;&nbsp;Massachusetts | 734394 | 14772 | 1515277 | 14771 |
| Revenue from Continuing Operations | 29548370 | 35517161 | 59592423 | 72253065 |
| Revenue from Discontinued Operations | 2282288 | 8065341 | 5911927 | 15405440 |
| **Total Revenue** | $**31830658** | $**43582502** | $**65504350** | $**87658505** |

---

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**22.** **DISCONTINUED OPERATIONS**

The operating results of the discontinued operations are summarized as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 24,<br>2022** | **December 25,<br>2021** | **December 24,<br>2022** | **December 25,<br>2021** |
| Revenue | $2282288 | $8065341 | $5911927 | $15405440 |
| Cost of Goods Sold | 439466 | 5672043 | 2630135 | 10899596 |
| Gross Profit | 1842822 | 2393298 | 3281792 | 4505844 |
| Expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;General and Administrative | 2134342 | 6329144 | 6853135 | 11946739 |
| &nbsp;&nbsp;&nbsp;Sales and Marketing | 15015 | 127844 | 58326 | 231647 |
| &nbsp;&nbsp;&nbsp;Depreciation and Amortization | 21107 | 1189331 | 894002 | 2411090 |
| &nbsp;&nbsp;&nbsp;Impairment Expense |  |  | (78433) |  |
| &nbsp;&nbsp;&nbsp;Gain on Disposal of Assets and Other Income |  |  | (36305166) | (597591) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total (Income) Expenses | $2170464 | $7646319 | $(28578136) | $13991885 |
| Income (Loss) from Discontinued Operations | (327642) | (5253021) | 31859928 | (9486041) |
| Other Expense: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest Expense | 1783685 | 4755126 | 5545446 | 9371955 |
| &nbsp;&nbsp;&nbsp;Accretion of Debt Discount and Loan Origination Fees |  | 3446949 | 398032 | 6987857 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Other Expense | 1783685 | 8202075 | 5943478 | 16359812 |
| Income (Loss) from Discontinued Operations Before Provision for Income Taxes | (2111327) | (13455096) | 25916450 | (25845853) |
| Provision for Income Tax Benefit (Expense) | (144651) | 1314496 | 216039 | (741238) |
| **Net Income (Loss) from Discontinued Operations** | $**(2255978)** | $**(12140600)** | $**26132489** | $**(26587091)** |

---

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

The carrying amounts of assets and liabilities in the disposal group are summarized as follows:

---

| | | |
|:---|:---|:---|
| | **December 24,<br>2022** | **June 25,<br>2022** |
| Carrying Amounts of the Assets Included in Discontinued Operations: |  |  |
| &nbsp;&nbsp;&nbsp;Cash and Cash Equivalents | $540828 | $1124076 |
| &nbsp;&nbsp;&nbsp;Restricted Cash | 5280 | 5280 |
| &nbsp;&nbsp;&nbsp;Accounts Receivable and Prepaid Expenses | 22019 | 334621 |
| &nbsp;&nbsp;&nbsp;Inventory | 4483051 | 6866833 |
| **TOTAL CURRENT ASSETS** <sup>(1)</sup> |  |  |
| &nbsp;&nbsp;&nbsp;Property and Equipment, Net | 9569610 | 41273597 |
| &nbsp;&nbsp;&nbsp;Operating Lease Right-of-Use Assets | 19111359 | 31543058 |
| &nbsp;&nbsp;&nbsp;Intangible Assets, Net | 10582559 | 40799146 |
| &nbsp;&nbsp;&nbsp;Other Assets | 458383 | 1181795 |
| **TOTAL ASSETS OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE** | **44773089** | **123128406** |
| Carrying Amounts of the Liabilities Included in Discontinued Operations: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts Payable and Accrued Liabilities | $979864 | $6295745 |
| &nbsp;&nbsp;&nbsp;Income Taxes Payable | 389677 | 1671380 |
| &nbsp;&nbsp;&nbsp;Other Current Liabilities | (5641) | 89069 |
| &nbsp;&nbsp;&nbsp;Current Portion of Operating Lease Liabilities | 2812765 | 4209512 |
| &nbsp;&nbsp;&nbsp;Current Portion of Finance Lease Liabilities |  | 174000 |
| **TOTAL CURRENT LIABILITIES** <sup>(1)</sup> |  |  |
| &nbsp;&nbsp;&nbsp;Operating Lease Liabilities, Net of Current Portion | 18398345 | 56410071 |
| &nbsp;&nbsp;&nbsp;Deferred Tax Liabilities | 5977580 | 6097597 |
| &nbsp;&nbsp;&nbsp;Notes Payable |  | 11100000 |
| **TOTAL NON-CURRENT LIABILITIES** <sup>(1)</sup> |  |  |
| **TOTAL LIABILITIES OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE** | $**28552590** | $**86047374** |

---

On August 22 2022, MME Florida LLC and its parent, MM Enterprises USA, LLC, a wholly-owned subsidiary of the Company closed on the Asset Purchase Agreement (the "Agreement") with Green Sentry Holdings, LLC, ("Buyer") for the sale of the Company's Florida-based assets, including its license, dispensaries, inventory and cultivation operations, and assumption of certain liabilities. The final sales price was $67,000,000, which was comprised of $63,000,000 in cash and $4,000,000 in liabilities to be assumed by the Buyer. The Buyer made a cash payment of $40,000,000 at closing, a cash payment of $11,500,000 on September 15, 2022 and is required to make one additional installment payment of $11,500,000 on or before March 15, 2023. The Company used $31,599,999 of the cash proceeds to repay the Senior Secured Term Loan Facility, and the Company received net cash proceeds of $19,558,947. Accordingly, the Company recognized a gain on sale of assets of $31,719,833, which is included in Net Income from Discontinued Operations for the six months ended December 24, 2022. All profit or loss relating to the Florida operations were eliminated from the Company's continuing operations and are shown as a single line item in the Condensed Consolidated Statement of Operation.

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**23.** **SUBSEQUENT EVENTS**

The Company has evaluated subsequent events through the date these Condensed Consolidated Financial Statements were issued and has concluded that no subsequent events have occurred that would require recognition in the Condensed Consolidated Financial Statements or disclosure in the Notes to the Condensed Consolidated Financial Statements.

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS**

*This management's discussion and analysis ("MD&A") of the financial condition and results of operations of MedMen Enterprises Inc. ("MedMen Enterprises", "MedMen", the "Company", "we" or "our") is for the three and six months ended December 24, 2022. The following discussion should be read in conjunction with, and is qualified in its entirety by, the Condensed Consolidated Financial Statements and the accompanying notes presented in Item 1 of this Form 10-Q and those discussed in Item 8 of the Company's Annual Report on Form 10-K (the "Form 10-K") filed with the SEC on September 9, 2022. Except for historical information, the discussion in this section contains forward-looking statements that involve risks and uncertainties. Future results could differ materially from those discussed below for many reasons, including the risks described in "Disclosure Regarding Forward-Looking Statements," Item 1A. "Risk Factors" and elsewhere in this Form 10-Q.*

We are a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act. Accordingly, we have omitted certain information called for by this Item as permitted by applicable scaled disclosure rules.

All references to "$" and "dollars" refer to U.S. dollars. References to C$ refer to Canadian dollars. Certain totals, subtotals and percentages throughout this MD&A may not reconcile due to rounding.

Our fiscal year is a 52/53-week year ending on the last Saturday in June or first Saturday in July. For the current interim period, the three and six months ended December 24, 2022 and December 25, 2021 refer to the 13 weeks ended therein.

**Overview**

MedMen is a cannabis retailer based in the U.S. offering a robust selection of high-quality products, including MedMen-owned brands, LuxLyte, and MedMen Red through its premium retail stores, proprietary delivery service, as well as curbside and in-store pick up. As of December 24, 2022 the Company operates 23 store locations across California (13), Nevada (3), Illinois (1), Arizona (1), Massachusetts (1), and New York (4).

On August 22, 2022, the Company completed the sale of its operations in the state of Florida, including its license, dispensaries, inventory and cultivation operations, to Green Sentry Holdings, LLC ("**Buyer**") at the final sales price of $67.0 million which comprised of $63.0 million in cash and $4.0 million in liabilities assumed by the Buyer. The Buyer made a cash payment of $40.0 million at closing, a cash payment of $11.5 million on September 15, 2022, and is required to make one additional installment payments of $11.5 million on or before March 15, 2023. As of December 24, 2022, net proceeds to the Company were $19.5 million after $31.6 million of the cash proceeds was used to repay the Senior Secured Term Loans with Hankey Capital. Proceeds of the transaction to the Company are used to fund operations and pay interest to Hankey Capital while the Senior Secured Term Loans remain outstanding and in default. In addition, the Company licensed the tradename "MedMen" to the Buyer for use in Florida for a period of two years, subject to termination rights, for a quarterly revenue-based fee. Proceeds from the licensure of the trade name have been minimal. All purchased assets and assumed liabilities related to Florida are excluded from our Condensed Consolidated Balance Sheets as of December 24, 2022 and all profits or losses from our Florida operations subsequent to August 22, 2022 are included in the Condensed Consolidated Statements of Operations. Refer to "*Note 22 – Discontinued Operations*" of the Condensed Consolidated Financial Statements in Item 1 of this Form 10-Q for further information.

Other developments during second quarter of 2022 included:

The launch of MOSS™, our own private label brand of cannabis products from our own cultivation facility in Mesa for sale in Arizona. The first shipments of Moss™ landed in our stores in late December.

We began construction of our second store in Illinois expecting to be complete in the Spring of 2023. The store is located in 15 miles northwest of Chicago and in similar proximity to our existing store in Oak Park, IL, in a dense suburban area near restaurants, coffee shops and parks.

We completed vendor-agreements in California with key brands in California which will allow us to secure optimal product assortment and pricing.

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

***COVID-19 Pandemic***

We continuously address the effects of the COVID-19 pandemic, a discussion of which is available in Item 1A "*Risk Factors*" of the 2022 Form 10-K. Our business and operating results for the three and six months ended December 24, 2022, continue to be impacted by the COVID-19 pandemic. The overall impact on our business continues to depend on the length of time that the pandemic continues, the impact on consumer purchasing behavior, macro-economic factors such as inflation, and the extent to which it affects our ability to raise capital, and the effect of governmental regulations imposed in response to the pandemic, which all remain uncertain at this time. We continue to implement and evaluate actions to strengthen our financial position and support the continuity of our business and operations.

**Financial Condition and Going Concern**

As of December 24, 2022, the Company had cash and cash equivalents of $15.6 million and working capital deficit of $137.4 million. The Company has incurred net losses from continuing operations of $15.1 million compared to $8.2 million for the six months ended December 24, 2022 and December 25, 2021, respectively. The conditions described above raise substantial doubt with respect to the Company's ability to meet its obligations for at least one year from the issuance of these Condensed Consolidated Financial Statements, and therefore, to continue as a going concern.

The Company plans to continue to fund its operations through the implementation and expansion of its cost savings plan, and various strategic actions, including the successful negotiations of lower costs of occupancy with our master lease landlord and other landlords, divestiture of non-core assets including but not limited to the current asset group held for sale, New York, as well continuing its on-going revenue and vendor strategy of market expansion and retail revenue and gross margin growth. We also need to obtain an extension or a refinancing of our debt-in-default with the secured senior lender. Our annual operating plan for fiscal year 2023 estimates we will be able to manage our ongoing operations. However, our cash needs are significant and not achievable with the current cash flow from operations. If the above strategic actions, for any reason, are inaccessible, it will have a significantly negative effect on the Company's financial condition. Additionally, we expect to continue to manage the Company's operating expenses and reduce its projected cash requirements through reduction of its expenses by delaying new store development, permanently or temporarily closing stores that are deemed to be performing below expectations, and/or implementing other restructuring activities. Furthermore, COVID-19 and the impact the global pandemic on the broader retail environment could also have a significant impact on the Company's financial position, results of operations, equity and or its access to capital and future financing.

As of December 24, 2022, the accompanying Consolidated Financial Statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The accompanying Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to our ability to continue as a going concern.

The following table summarizes certain aspects of the Company's financial condition as of December 24, 2022 and June 25, 2022:

---

| | | | | |
|:---|:---|:---|:---|:---|
| *($ in Millions)* | **December 24,<br>2022** | **June 25,<br>2022** | **$ Change** | **% Change** |
| Cash and Cash Equivalents | $15.6 | $10.8 | $4.8 | 45% |
| Total Current Assets | $100.2 | $161.5 | $(61.3) | (38%) |
| Total Assets | $238.5 | $323.2 | $(84.7) | (26%) |
| Total Current Liabilities | $237.6 | $319.6 | $(81.9) | (26%) |
| Notes Payable, Net of Current Portion | $74.1 | $74.4 | $(0.3) | —% |
| Total Liabilities | $567.3 | $641.7 | $(74.5) | (12%) |
| Total Shareholders' Equity | $(328.8) | $(318.5) | $(10.3) | 3% |
| Working Capital Deficit | $(137.4) | $(158.1) | $20.7 | (13%) |

---

In August 2022, the Company completed the sale of its operations in the state of Florida at the final sales price of $67,000,000 which comprised of $63,000,000 in cash and $4,000,000 in liabilities to be assumed by the Buyer. The Buyer made a cash payment of $40,000,000 at closing, $11,500,000 on September 15, 2023, and is required to make an additional installment payment of $11,500,000 on or before March 15, 2023. During the fiscal third quarter of 2022, net proceeds to

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

the Company were $19,558,947 after a principal repayment of $31,599,999 on the Senior Secured Term Loans with Hankey Capital. The final cash payment of $11,500,000 remains due and receivable as of December 24, 2022. The Senior Secured Term Loans remains outstanding and in default as of December 24, 2022.

The $20.7 million improvement in working capital deficit was primarily related to the $31.6 million principal repayment on the Senior Secured Term Loans that matured on July 31, 2022 and August 1, 2022. The Company's working capital will be significantly impacted by continued operations and growth in retail operations and the continued stewardship of the Company's financial resources. The ability to fund working capital needs will also be dependent on the Company's ability to raise additional debt and equity financing and execute cost savings plans.

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**Results of Operations**

Our consolidated results, in millions, except for per share and percentage data, for the three and six months ended December 24, 2022, compared to the three and six months ended December 25, 2021, are as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | | | **Six Months Ended** | **Six Months Ended** | | |
|<br>*($ in Millions)* | **December 24,<br>2022** | **December 25,<br>2021** |<br>**$ Change** |<br>**% Change** | **December 24,<br>2022** | **December 25,<br>2021** |<br>**$ Change** |<br>**% Change** |
|  | *(unaudited)* | *(unaudited)* |  |  | *(unaudited)* | *(unaudited)* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Revenue | $29.6 | $35.5 | $(5.9) | (17%) | $59.6 | $72.3 | $(12.7) | (18%) |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of Goods Sold | 14.5 | 17.6 | (3.1) | (18%) | 29.6 | 37.0 | (7.4) | (20%) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross Profit | 15.1 | 17.9 | (2.8) | (16%) | 30.0 | 35.3 | (5.3) | (15%) |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating Expenses: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and Administrative | 18.3 | 31.3 | (13.0) | (42%) | 36.5 | 63.9 | (27.4) | (43%) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales and Marketing | 0.6 | 1.0 | (0.4) | (40%) | 1.0 | 1.6 | (0.6) | (38%) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and Amortization | 3.5 | 6.4 | (2.9) | (45%) | 7.4 | 12.2 | (4.8) | (39%) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Realized and Unrealized Changes in Fair Value of Contingent Consideration |  | (0.3) | 0.3 |  | (0.9) | (0.3) | (0.6) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment Expense | 5.1 |  | 5.1 | —% | 6.7 | 0.4 | 6.3 | 1575% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Operating (Income) Expense | (5.6) | 0.6 | (6.2) | (1033%) | (7.5) | 2.8 | (10.3) | (368%) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Operating Expenses | 21.8 | 39.0 | (21.3) | (55%) | 43.2 | 80.7 | (21.3) | (26%) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss from Operations | (6.7) | (21.1) | 14.4 | (68%) | (13.2) | (45.4) | 32.2 | (71%) |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-Operating (Income) Expenses: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest Expense | 9.7 | 8.1 | 1.6 | 20% | 19.7 | 16.2 | 3.5 | 22% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accretion of Debt Discount and Loan Origination Fees | 1.5 | 1.3 | 0.2 | 16% | 2.9 | 7.6 | (4.7) | (62%) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in Fair Value of Derivatives | (3.9) | (14.1) | 10.2 | (72%) | (3.1) | (16.2) | 13.1 | (81%) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on Extinguishment of Debt |  |  |  |  |  | (10.2) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Non-Operating Expense | 7.3 | (4.8) | 12.1 | (252%) | 19.5 | (2.6) | 22.1 | (850%) |
| Loss from Continuing Operations Before Provision for Income Taxes | (14.0) | (16.4) | 2.4 | (15%) | (32.7) | (42.8) | 10.1 | (24%) |
| Provision for Income Tax Expense | (1.1) | 8.1 | (9.2) | (114%) | (6.8) | (11.6) | 4.8 | (41%) |
| Net Loss from Continuing Operations | (15.1) | (8.2) | (6.9) | 84% | (39.4) | (54.4) | 15.0 | (28%) |
| Net Income (Loss) from Discontinued Operations, Net of Taxes | (2.3) | (12.1) | 9.8 | (81%) | 26.1 | (26.6) | 52.7 | (198%) |
| Net Income (Loss) | (17.3) | (20.4) | 3.1 | (15%) | (13.3) | (81.0) | 67.7 | (84%) |
| Net Loss Attributable to Non-Controlling Interest | (1.1) | (1.3) | 0.2 | (15%) | (1.2) | (6.6) | 5.4 | (82%) |
| **Net Loss Attributable to Shareholders of MedMen Enterprises Inc.** | $**(16.2)** | $**(19.0)** | $**2.8** | **(15** **%)** | $**(12.0)** | $**(74.4)** | $**62.4** | **(84** **%)** |
| EBITDA from Continuing Operations (Non-GAAP) | $0.7 | $(0.1) | $0.8 | (800%) | $(2.6) | $(5.8) | $3.2 | (55%) |
| Adjusted EBITDA from Continuing Operations (Non-GAAP) | $— | $(12.0) | $12 | (100%) | $0.2 | $(14.2) | $14.4 | (101%) |

---

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

***Revenue***

Revenue for the three months ended December 24, 2022 was $29.6 million, a decrease of $6.0 million, or 17%, compared to revenue of $35.5 million for the three months ended December 24, 2021. Revenue for the six months ended December 24, 2022 was $59.6 million, a decrease of $12.7 million, or 18%, compared to revenue of $72.3 million for the six months ended December 25, 2021.

Revenue in various states in which we operate is as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | | | **Six Months Ended** | **Six Months Ended** | | |
|<br>*($ in Millions)* | **December 24,<br>2022** | **December 25,<br>2021** |<br>**$ Change** |<br>**% Change** | **December 24,<br>2022** | **December 25,<br>2021** |<br>**$ Change** |<br>**% Change** |
| California | $19.6 | $23.4 | $(3.8) | (16)% | $39.5 | $48.0 | $(8.5) | (18)% |
| Nevada | 2.8 | 3.9 | (1.1) | (28)% | 5.8 | 7.9 | (2.1) | (27)% |
| Illinois | 3.1 | 4.1 | (1.0) | (24)% | 6.6 | 8.4 | (1.8) | (21)% |
| Arizona | 3.3 | 4.2 | (0.9) | (21)% | 6.1 | 7.9 | (1.8) | (23)% |
| Massachusetts | 0.7 |  | 0.7 | —% | 1.5 |  | 1.5 | —% |
| Revenue from Continuing Operations | $29.5 | $35.5 | $(6.0) | (17)% | $59.6 | $72.3 | $(12.7) | (18)% |
| Revenue from Discontinued Operations | $2.3 | $8.1 | $(5.8) | (72)% | $5.9 | $15.4 | $(9.5) | (62)% |
| **Total Revenue** | $**31.8** | $**43.6** | $**(11.8)** | **(27)%** | $**65.5** | $**87.7** | $**(22.2)** | **(25)%** |

---

Overall, across all markets, for the periods presented, we experienced declines in revenue.

In California, revenue for the three and six months ended December 24, 2022 experienced a decline of $3.8 million or 16% and $8.5 million or 18%, respectively, over the same prior year period. The change is primarily driven by lower basket size, inconsistent and / or lower traffic to the stores which was slightly partially offset by flat conversion rates. We believe we were also affected by the status of the cannabis supply in this State. California continues to deal with high levels of cannabis production, which we believe has flooded the legal and illegal market with quality cannabis flower increasing competition and decreasing market share. In addition, the increase in new dispensaries within key markets, more aggressive promotional cadence by all dispensaries, including ours, has resulted in a saturated market wherein the California cannabis consumer has an increased number of choices for cannabis products at discounted pricing. During the quarter, we continued to increase our focus on product portfolio and product selection, expanding vendor relationships, engaging in allowable marketing strategies and continued efforts to develop our private label products.

In Nevada, revenue for the three and six months ended December 24, 2022 experienced a decline of $1.0 million or 27% and $2.1 million or 27%, respectively, over the same prior year period. We experienced a decline in basket size as well as traffic and conversion rates. Nevada noted an overall decline in legal cannabis sales primarily related to a maturing industry, lower disposable income and a revenue base heavily reliant on tourism.

In Illinois, revenue for the three and six months ended December 24, 2022 experienced a decline of $1.0 million or 25% and $1.8 million or 21%, respectively, over the same prior year period. We continue to face market pressure from additional licenses issued by surrounding municipalities as part of Illinois' efforts to promote equality and accessible locations for the consumer. We have made great efforts in testing new promotional messaging that, if marketed properly, can increase foot traffic and revenue. We have plans to open a second store in Illinois in the Spring of 2023 located 15 miles northwest of Chicago and within similar proximity to our existing store in Oak Park, in a dense suburban area near restaurants, coffee shops and parks.

In Arizona, revenue for the three and six months ended December 24, 2022 experienced a decline of $0.8 million or 20% and $1.7 million or 22% respectively over the same prior year period. This decrease resulted from a decline in medical-use sales because of a maturing recreational cannabis industry. Arizona is also experiencing an increase in new dispensary openings, that similar to California, has resulted in a saturated market. Exacerbating the increase in dispensary openings, is the increase in aggressive promotional cadences by these dispensaries. We continue our efforts to finding the optimal product selection that can meet the demands of both medical and recreational customers including the launch of our private label products, Moss™, from our own cultivation facility in Mesa. The first shipments of Moss™ landed in our stores in late December.

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

In Massachusetts, revenue for the three and six months ended December 24, 2022 experienced an increase of $0.7 million and $1.5 million, respectively. Our store near Fenway Park opened December 2021 with no comparable sales for this reporting period.

During our first fiscal quarter, we completed the sale of our Florida-based assets. We continue to hold for sale our New York-based assets which are presented as discontinued operations.

***Cost of Goods Sold and Gross Profit***

Cost of goods sold for the three and six months ended December 24, 2022 was $14.5 million and $29.6 million compared to $17.6 million and $37.0 million for the three and six months ended December 25, 2021 respectively, with a decrease of $3.1 million, or 18% and $7.4 million or 20% respectively.

Gross profit for the three and six months ended December 24, 2022 was $15.1 million and $30.0 million compared to $17.9 million and $35.3 million for the three and six months ended December 25, 2021 respectively, with a decrease of $2.8 million, or 16% and $5.3 million or 15%, respectively. Gross margin for the three and six months ended December 24, 2022 was 51% and 50%, respectively, compared to gross margin of 50% and 49% for the three and six months ended December 25, 2021 respectively. The improvement in gross margin resulted from our continuous efforts to develop vendor programs that reduced our cost of goods sold, as well as our success in lowering costs of production at our cultivation centers.

***Operating Expenses***

Operating expenses for the three and six months ended December 24, 2022 was $21.8 million and $43.2 million compared to $39.0 million and $80.7 million for the three and six months ended December 25, 2021 respectively, with a decrease of $17.2 million, or 44% and $37.5 million or 46% respectively. These changes were primarily attributable to our efforts and focus on our cost management strategy as well as the factors discussed below.

General and administrative expenses ("G&A") for the three and six months ended December 24, 2022 was $18.3 million and $36.5 million compared to $31.3 million and $63.9 million for the three and six months ended December 25, 2021 respectively, with a decrease of $13.0 million, or 41% and $27.5 million or 43% respectively. Key drivers of the decrease in G&A for the three months ended December 24, 2022 include reductions in rent expense of $1.7 million, salaries of $3.5 million, professional fees of $5.7 million, deal costs of $1.2 million and other general expenses of $2.9 million, partially offset by an increase in share-based compensation of $1.4 million. Management continues to focus on reducing company-wide G&A. We expect G&A will continue to decrease in fiscal year 2023 as compared to prior year.

Sales and marketing expenses for the three and six months ended December 24, 2022 was $0.6 million and $1.0 million compared to $1.0 million and $1.6 million for the three and six months ended December 25, 2021 respectively, with a decrease of $0.5 million, or 45% and $0.6 million or 38% respectively.

Depreciation and amortization for the three and six months ended December 24, 2022 was $3.5 million and $7.4 million compared to $6.4 million and $12.2 million for three and six months ended December 25, 2021 respectively, with a decrease of $2.9 million, or 45% and $4.8 million or 39% respectively. The overall decrease is attributable a lower carrying basis of our long-lived assets as a result of the impairment charge recorded in the fourth quarter of 2022 and a delay in new capital projects. We are currently evaluating the long-term benefits of continuing to pursue the build out of some of our locations that are not yet opened or constructed. We are in negotiations with the landlords of our unfinished locations in California and Massachusetts in an effort to reach the best outcome for all parties including the communities that live and work near these unfinished locations possibly deterring from market values.

Impairment expense for the three and six months ended December 24, 2022 was $5.1 million and $6.7 million compared to nil and $0.4 million for the three and six months ended December 25, 2021 respectively, with an increase of $5.1 million and $6.3 million, or nil and 1443%, respectively.

Other operating (income) expense for the three and six months ended December 24, 2022 was other operating income of $5.6 million and $7.5 million compared to other operating expense of $0.6 million and $2.8 million for the three and six months ended December 25, 2021 respectively, with a decrease in other operating expense of $6.3 million, or 993% and $10.4 million or 367% respectively. The decrease in other operating expense of $6.3 million for the three months ended December 24, 2022 was primarily due to a $2.1 million increase in gain on lease terminations, a net $3.5 million gain on legal settlements and recognition of $1.5 million in sublease income, partially offset by a $1.3 million increase in loss on

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

disposals of assets. The decrease in other operating expense of $10.4 million for the six months ended December 24, 2022 was primarily due to the net $3.5 million gain on legal settlements, recognition of $3.0 million in sublease income, a $3.6 million increase in gain on lease terminations, partially offset by a $2.3 million decrease in restructuring and reorganization expenses and a $1.5 million increase in loss on disposals of assets.

***Non-Operating Expense***

Non-operating expense for the three and six months ended December 24, 2022 was $7.3 million and $19.5 million compared to non-operating income of $4.8 million and $2.6 million for the three and six months ended December 25, 2021 respectively, with an increase of $12.1 million, or 253% and $22.1 million or 845% respectively. The increase in non-operating expense for the three months ended December 24, 2022 was primarily due a $10.2 million devaluation in the fair value of our derivatives. The increase in non-operating expense for the six months ended December 24, 2022 was primarily due to a $13.1 million devaluation in the fair value of our derivatives coupled with a decrease in gain on extinguishment of debt of $10.2 million and increase in interest expense of $3.5 million, partially offset by a decrease of $4.7 million in the accretion of our debt discount and loan origination fees.

***Provision for Income Taxes***

MedMen is subject to income taxes in the jurisdictions in which it operates and, consequently, income tax expense is a function of the allocation of taxable income by jurisdiction and the various activities that impact the timing of taxable events. As we operate in the legal cannabis industry, we are subject to the limits of Internal Revenue Code ("IRC") Section 280E under which we are only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E and a higher effective tax rate than most industries. However, California does not conform to IRC Section 280E and, accordingly, we deduct all operating expenses on MedMen's California Franchise Tax Returns.

The provision for income taxes for the three and six months ended December 24, 2022 was $(1.1) million and $(6.8) million compared to $8.1 million and $(11.6) million for the three and six months ended December 25, 2021 respectively, with a decrease of $9.2 million, or 113% and $4.8 million or 42% respectively. The change is primarily due to the Company's forecasted income and related IRC Section 280E expenditures.

***Net Loss***

Net loss from continuing operations for the three and six months ended December 24, 2022 was $15.1 million and $39.4 million compared to $8.2 million and $54.4 million for three and six months ended December 25, 2021 respectively. For the three and six months ended December 24, 2022, net loss from continuing operations was favorably impacted by the Company's continued efforts to optimize selling, general and administrative costs and right-size the Company's corporate infrastructure.

**Non-GAAP Financial Measures**

EBITDA from Continuing Operations and Adjusted EBITDA from Continuing Operations are financial measures that are not defined under GAAP. We define EBITDA as net income (loss), or "earnings", before interest, income taxes, depreciation and amortization. We define Adjusted EBITDA as EBITDA before: (i) transaction costs and restructuring costs; (ii) non-cash share-based compensation expense; (iii) fair value changes in derivative liabilities and contingent consideration; (iv) (gains) losses on disposal of assets, assets held for sale, extinguishment of debt and lease terminations; and (v) other one-time charges for non-cash operating costs. These financial measures are metrics that have been adjusted from the GAAP net income (loss) measure in an effort to provide readers with a normalized metric in making comparisons more meaningful across the cannabis industry, as well as to remove non-recurring, irregular and one-time items that may otherwise distort the GAAP net income measure. Other companies in our industry may calculate this measure differently, limiting their usefulness as comparative measures.

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

***Reconciliations of GAAP Measures to Non-GAAP Financial Measures***

The table below reconciles Net Loss to EBITDA from Continuing Operations and Adjusted EBITDA from Continuing Operations for the periods indicated.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
|<br>*($ in Millions)* | **December 24, 2022** | **December 25, 2021** | **December 24, 2022** | **December 25, 2021** |
| Net Loss | $(17.3) | $(20.4) | $(13.3) | $(81.0) |
| Less: Net (Income) Loss from Discontinued Operations, Net | 2.3 | 12.1 | (26.1) | 26.6 |
| Add (Deduct) Impact of: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Interest and Other Financing Costs <sup>(1)</sup> | 11.2 | 9.4 | 22.6 | 23.9 |
| &nbsp;&nbsp;&nbsp;Provision for Income taxes | 1.1 | (8.1) | 6.8 | 11.6 |
| &nbsp;&nbsp;&nbsp;Amortization and Depreciation | 3.5 | 6.9 | 7.5 | 13.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EBITDA from Continuing Operations | $0.8 | $(0.1) | $(2.5) | $(5.8) |
| Other Operating (Income) Expense: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Share-based Compensation | $2.1 | $0.7 | 3.0 | 2.4 |
| &nbsp;&nbsp;&nbsp;Change in Fair Value of Derivative Liabilities | (3.9) | (14.1) | (3.1) | (16.2) |
| &nbsp;&nbsp;&nbsp;Change in Fair Value of Contingent Consideration |  | (0.3) | (0.9) | (0.3) |
| &nbsp;&nbsp;&nbsp;Impairment Expense | 5.1 |  | 6.7 | 0.4 |
| &nbsp;&nbsp;&nbsp;(Gain) Loss on Disposals of Assets | 1.2 | (0.1) | 1.4 | (0.1) |
| &nbsp;&nbsp;&nbsp;Restructuring and Reorganization Expense |  | 1.6 | 0.9 | 5.6 |
| &nbsp;&nbsp;&nbsp;Gain on Lease Terminations | (1.9) | 0.2 | (3.5) | 0.2 |
| &nbsp;&nbsp;&nbsp;(Gain) Loss on Disposal of Assets Held for Sale | (0.1) |  | 0.5 |  |
| &nbsp;&nbsp;&nbsp;Legal Settlements | (3.5) |  | (3.5) |  |
| &nbsp;&nbsp;&nbsp;Non-Cash Rent Expense | 0.9 |  | 1.6 |  |
| &nbsp;&nbsp;&nbsp;Other Non-Cash Operating Costs | (0.6) | 0.2 | (0.4) | (0.3) |
| &nbsp;&nbsp;&nbsp;Total Adjustments | (0.7) | (11.8) | 2.7 | (8.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA from Continuing Operations | $0.1 | $(11.9) | $0.2 | $(14.1) |

---

_____________________________________

*(1)*For the current period, net interest and other financing costs now include accretion of debt discount and loan origination fees of $1.5 million for the three months ended December 24, 2022 and $2.9 million for the six months ended December 24, 2022. The prior year amount of $1.3 million for the three months ended December 25, 2021 and $7.6 million for the six months ended December 25, 2021 have been reclassified for consistency with the current year presentation. Accretion of debt discount was previously excluded from the reconciliation of Net Loss to EBITDA from Continuing Operations and Adjusted EBITDA from Continuing Operations.

EBITDA from Continuing Operations represents the Company's current operating profitability and ability to generate cash flow and includes significant non-cash operating costs. Considering these adjustments, the Company had EBITDA from Continuing Operations for the three and six months ended December 24, 2022 of $0.8 million and $(2.5) million compared to $(0.1) million and $(5.8) million for the three and six months ended December 25, 2021 respectively, with an increase of $0.9 million, or 900% and $3.3 million or 57% respectively. The improvement in EBITDA from Continuing Operations was primarily due to the Company's continued cost-saving strategies, lower operating costs at the cultivation facility in Arizona and elimination of high operating costs from the licensing and management agreement with an unrelated third party now operating the previously owned cultivation centers in California and Nevada, which includes lower rents.

Adjusted EBITDA from Continuing Operations for the three and six months ended December 24, 2022 was $0.1 million and $0.2 million compared to $(11.9) million and $(14.1) million for the three and six months ended December 25, 2021 respectively. The improvement is primarily due to the decrease in general and administrative expenses. The financial performance of the Company is expected to further improve as the Company works towards profitability and coupled with significant deleveraging of its balance sheet, will reposition the Company for growth.

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

Refer to Item 2 "*Liquidity and Capital Resources"* for further discussion of management's future outlook.

**Cash Flows**

The following table summarizes the Company's consolidated cash flows for the six months ended December 24, 2022 and December 25, 2021:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Six Months Ended** | **Six Months Ended** | | |
|<br>*($ in Millions)* | **December 24, 2022** | **December 25, 2021** |<br>**$ Change** |<br>**% Change** |
| Net Cash Used in Operating Activities | $(8.3) | $(49.9) | $41.6 | (83%) |
| Net Cash Provided by (Used in) Investing Activities | 45.5 | (7.6) | 53.1 | (701%) |
| Net Cash (Used in) Provided by Financing Activities | (32.4) | 93.2 | (125.5) | (135%) |
| Net Increase in Cash and Cash Equivalents | 4.8 | 35.7 | (30.9) | (87%) |
| Cash Included in Assets Held for Sale |  | (0.3) | 0.3 | (100%) |
| Cash and Cash Equivalents, Beginning of Period | 10.8 | 11.6 | (0.8) | (7%) |
| **Cash and Cash Equivalents, End of Period** | $**15.6** | $**47.0** | $**(31.4)** | **(67** **%)** |

---

***Cash Flow from Operating Activities***

Net cash used in operating activities for the six months ended December 24, 2022 was $8.3 million compared to $49.9 million net cash used for operating activities for the six months ended December 25, 2021. The decrease was primarily driven by the decrease in general and administrative expenses as described in "*Results of Operations*" above.

***Cash Flow from Investing Activities***

Net cash provided by investing activities for the six months ended December 24, 2022 was $45.5 million compared to $7.6 million net cash used in investing activities six months ended December 25, 2021. This was primarily due to the $51.5 million in cash proceeds from the sale of the Company's operations in the state of Florida during the current period.

***Cash Flow from Financing Activities***

Net cash used in financing activities for the six months ended December 24, 2022 was $32.4 million compared to $93.2 million net cash provided by financing activities for six months ended December 25, 2021. During the current period, the Company used $31.6 million of the cash proceeds from the sale of its Florida-based operations to make principal repayments on the Senior Secured Term Loan. Whereas during the comparative prior period, the Company completed a private placement with Serruya Private Equity Inc. ("SPE") resulting in an equity investment of $100.0 million.

**Liquidity and Capital Resources**

The primary need for liquidity is to fund working capital requirements of the business, including operationalizing existing licenses, capital expenditures, debt service and acquisitions. The primary source of liquidity has primarily been private and/or public financing and to a lesser extent by cash generated from sales. The ability to fund operations, to make planned capital expenditures, to execute on the growth/acquisition strategy, to make scheduled debt and rent payments and to repay or refinance indebtedness depends on the Company's future operating performance and cash flows, which are subject to prevailing economic conditions and financial, business and other factors, some of which are beyond its control. Liquidity risk is the risk that the Company will not be able to meet its financial obligations associated with financial liabilities. The Company manages liquidity risk through the management of its capital structure.

**Off-Balance Sheet Arrangements**

The Company has no material undisclosed off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on its results of operations, financial condition, revenues or expenses, liquidity, capital expenditures or capital resources that are material to investors.

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**Critical Accounting Policies, Significant Judgments and Estimates and Recent Accounting Pronouncements**

There have been no changes in critical accounting policies, estimates and assumptions from the information provided in "Management's Discussion and Analysis of Financial Conditions and Results of Operations" included in the Form 10 for the fiscal year ended June 25, 2022 that have a significant effect on the amounts recognized in the Condensed Consolidated Financial Statements as of and for the fiscal quarter ended December 24, 2022. See "*Note 2 – Summary of Significant Accounting Policie*s" in the Condensed Consolidated Financial Statements in Item 1 for recently adopted accounting standards. For more information on the Company's critical accounting estimates, refer to the "*Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations"* of the Annual Report on Form 10-K for the fiscal year ended June 25, 2022. In addition, a detailed description of our critical accounting policies and recent accounting pronouncements are detailed in Part I, "*Item 8. Financial Statements and Supplementary Data*" of the Annual Report on Form 10-K for the fiscal year ended June 25, 2022.

**Transactions with Related Parties**

As of December 24, 2022 and June 25, 2022 there were no amounts due from or due to related parties that were recorded in the Consolidated Balance Sheets. Refer to "*Note 19 – Related Party Transactions"* of the Consolidated Financial Statements under Part I, "Item 1. Notes to Condensed Consolidated Financial Statements", which is incorporated in this item by reference.

The Company's Board of Directors each receive quarterly fees of $200,000 of which one-third is paid in cash and two-thirds is paid in Class B Subordinate Voting Shares.

***Senior Secured Convertible Credit Facility***

As of December 24, 2022, the Company has drawn down a total of $165.0 million on the Convertible Facility, has accrued paid-in-kind interest of $51.1 million with an aggregate weighted average conversion price of approximately $0.24 per share, and an aggregate of 192,981,432 warrants with a weighted average exercise price of $0.15 per share.

**Emerging Growth Company Status**

The Company is an "emerging growth company" as defined in the Section 2(a) of the Exchange Act, as modified by the Jumpstart Our Business Start-ups Act of 2012, or the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 13(a) of the Exchange Act for complying with new or revised accounting standards applicable to public companies. The Company has elected to take advantage of this extended transition period and as a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Information not required to be filed by smaller reporting companies.

**ITEM 4. CONTROLS AND PROCEDURES**

**Evaluation of Disclosure Controls and Procedures**

Pursuant to Rules 13a-15(b) and 15-d-15(b) under the Securities Exchange Act of 1934, as amended ("Exchange Act"), as of December 24, 2022, the Company carried out an evaluation, with the participation of the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer of the effectiveness of the Company's disclosure controls and procedures as of the end of the period covered by this report.

The term "disclosure controls and procedures", as defined under Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

its principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Based upon that evaluation and the identification of the material weakness described herein, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective, at the reasonable assurance level, as of the end of our last fiscal year end, June 25, 2022, and continues as such as of the end of the period covered by this report.

**Changes in Internal Control Over Financial Reporting** 

For fiscal year 2022, management identified a material weakness determining that the Company's financial recordkeeping process was deficient and that it does not have effective controls over the period-end reconciliation process. The reconciliation process was not being performed in a manner that will detect and correct errors on a timely basis, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• general ledgers are not being reviewed regularly for assets that may not be recoverable or viable,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• review procedures for balance sheet account reconciliations and manual journal entries were not performed, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• some accounts and balances are not being reconciled regularly, and/or account reconciliations that are being completed do not properly address or adjust reconciling items.

Management plans to implement measures designed to improve its internal control over financial reporting to remediate material weaknesses described above by standardizing the monthly reconciliation process for material accounts and balances with formalized procedures. Material non-standard journal entries recorded in the accounting system will be reviewed for the various applicable accounting assertions including recoverability and validity. While the Company is actively engaged in the implementation of its remediation efforts to address this internal control weakness, the actions we have taken are subject to continued review, supported by confirmation and testing by management. Accordingly, the material weakness will not be considered fully remediated until the new control procedures are implemented for a sufficient period of time and management has concluded that these controls are operating effectively which we anticipate will occur in the ensuing months.

Except as noted above, there were no changes in our internal control over financial reporting during the three months ended December 24, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**Inherent Limitations on Effectiveness of Controls**

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements attributable to error or fraud will not occur or that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Assessments of any evaluation of controls' effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements as a result of error or fraud may occur and not be detected.

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**PART II — OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

For a description of our legal proceedings, please see the description set forth in the "Claims and Litigation" section in Note 18 - Commitments and Contingencies in the notes to consolidated financial statements in Item 1 of Part I of this Form 10-Q, which is incorporated herein by reference.

**ITEM 1A. RISK FACTORS.**

Smaller reporting companies are not required to provide the information required by this Item.

**ITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS**

None.

**Purchases of Equity Securities by the Issuer and Affiliated Purchasers**

None.

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

See discussion of Senior Secured Term Loan in "*Note 10 – Notes Payable*" under Part I, "Item 1. Notes to Condensed Consolidated Financial Statements", which is incorporated in this item by reference.

**ITEM 4. MINE SAFETY DISCLOSURE**

Not applicable.

**ITEM 5. OTHER INFORMATION**

None.

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**ITEM 6. EXHIBITS**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
|<br>**Exhibit No.** |<br>**Exhibit Description** | **Form** | **File No.** | **Exhibit** | **Filing Date** | **Filed/<br>Furnished<br>Herewith** |
| 31.1 | <u>[Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.](mmen_exh311x122422xceocert.htm)</u> |  |  |  |  | ✓ |
| 31.2 | <u>[Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.](mmen_exh312x122422xcfocert.htm)</u> |  |  |  |  | ✓ |
| 32.1\* | <u>[Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](mmen_exh321x122422xceocfoc.htm)</u> |  |  |  |  | ✓ |
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |  |  |  |  |  |
| 101.SCH | XBRL Taxonomy Extension Schema Document. |  |  |  |  | ✓ |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document. |  |  |  |  | ✓ |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document. |  |  |  |  | ✓ |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document. |  |  |  |  | ✓ |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document. |  |  |  |  | ✓ |
| 104 | Cover Page Interactive Data File. (Formatted as Inline XBRL and contained in Exhibit 101.) |  |  |  |  | ✓ |

---

____________________________________

\*This exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.

------

<u>[Table of](#icb45d2f215b8492596aebaa3e07e76d2_7)</u>[Contents](#icb45d2f215b8492596aebaa3e07e76d2_7)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: February 2, 2023 | **MEDMEN ENTERPRISES INC** | **MEDMEN ENTERPRISES INC** |
|  | */s/* Ana Bowman | */s/* Ana Bowman |
|  | By: | Ana Bowman |
|  | Its: | Chief Financial Officer |

---

## Exhibit 31.1

**Exhibit 31.1**

**CEO Certification**

**Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Edward J. Record, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this report on Form 10-Q of MedMen Enterprises Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a

material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | | |
|:---|:---|:---|:---|
| Date: | February 2, 2023 | By: | /s/ Edward J. Record |
|  |  |  | Edward J. Record |
|  |  |  | Chief Executive Officer |

---

## Exhibit 31.2

**Exhibit 31.2**

**CFO Certification**

**Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Ana Bowman, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this report on Form 10-Q of MedMen Enterprises Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a

material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | | |
|:---|:---|:---|:---|
| Date: | February 2, 2023 | By: | /s/ Ana Bowman |
|  |  |  | Ana Bowman |
|  |  |  | Chief Financial Officer |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Annual Report on Form 10-Q for the period ended December 24, 2022 of MedMen Enterprises Inc. (the "Company") as filed with the Securities and Exchange Commission on the date hereof (the "Report"), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods presented in the Report.

---

| | |
|:---|:---|
| By: | /s/ Edward J. Record |
|  | Edward J. Record |
|  | Chief Executive Officer |
|  | February 2, 2023 |
| By: | /s/ Ana Bowman |
|  | Ana Bowman |
|  | Chief Financial Officer |
|  | February 2, 2023 |

---

400643091.2<br>